WO1990003446A1 - Nucleic acid probes containing improved molecular switch, and assays and kits incorporating same - Google Patents

Nucleic acid probes containing improved molecular switch, and assays and kits incorporating same Download PDF

Info

Publication number
WO1990003446A1
WO1990003446A1 PCT/US1989/004275 US8904275W WO9003446A1 WO 1990003446 A1 WO1990003446 A1 WO 1990003446A1 US 8904275 W US8904275 W US 8904275W WO 9003446 A1 WO9003446 A1 WO 9003446A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
probe
rna
switch
hybridized
Prior art date
Application number
PCT/US1989/004275
Other languages
French (fr)
Inventor
Paul M. Lizardi
Fred Russell Kramer
Sanjay Tyagi
Cesar Eduardo Guerra
Hilda M. Lomeli Buyoli
Original Assignee
Public Health Research Institute Of The City Of New York, Inc.
The Salk Institute For Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public Health Research Institute Of The City Of New York, Inc., The Salk Institute For Biological Studies filed Critical Public Health Research Institute Of The City Of New York, Inc.
Priority to AU43466/89A priority Critical patent/AU647376B2/en
Priority to DE68926302T priority patent/DE68926302T2/en
Priority to EP89911480A priority patent/EP0436644B1/en
Publication of WO1990003446A1 publication Critical patent/WO1990003446A1/en
Priority to DK056091A priority patent/DK56091A/en
Priority to FI911536A priority patent/FI911536A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6867Replicase-based amplification, e.g. using Q-beta replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/682Signal amplification
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Definitions

  • This invention relates to the field of bioassays that involve nucleic acid hybridization probes. These bioassays are useful for the detection of specific genes, gene segments or RNA molecules.
  • the assays are useful clinically, for, e.g., tissue, blood and urine samples, as well as in food technology, agriculture, and biological research.
  • nucleic acid hybridization probes for bioassays.
  • One of the early papers in the field directed to assays for DNA is Gillespie, D. and Spiegel an, S., A Quantitative Assay for DNA-RNA Hybrids with DNA Immobilized on a Membrane, J. Mol. Biol. 22:829-842 (1965).
  • an assay involves separating the nucleic acid polymer chains in a sample, as by melting, fixing the separated DNA strands to a nitrocellulose membrane, and then introducing a probe sequence which is complementary to a unique sequence of the material being sought, the "target" material, and incubating to hybridize probe segments to complementary target segments, if targets are present.
  • Non-hybridized probes are removed by known washing techniques, and - then the amount of probe remaining is determined by one of a variety of techniques outlined below which provides a measurement of the amount of targets in the sample.
  • the present invention is directed to the methods and means, including assays and pharmaceutical kits containing requisite reagents and means, for detecting in an in vitro or ex vitro setting the presence of nucleic acid species.
  • a second approach is to link a signal generating system to the probe.
  • Examples are enzymes such as peroxidase.
  • Probes are then incubated with a color- forming substrate.
  • Leary, J.J. , Brigati, D.J. and Ward, D.C., Rapid and Sensitive Colorimetric Method for Visualizing Biotin-Labeled DNA Probes Hybridized' to DNA or RNA Immobilized on Nitrocellulose: Bio- Blots, Proc. Natl. Acad. Sci. USA 80:4045-4049 (1983).
  • Such amplification reduces the minimum number of target molecules which can be detected.
  • nonspecific binding of probes has limited the improvement in sensitivity as compared to radioactive tagging to roughly an order of magnitude, i.e., to a minimum of roughly 100,000 target molecules.
  • the probe is complementary only to the beginning of a target sequence but, through an enzymatic process, serves as a primer for replication of an entire target. Each repetition of the process results in another doubling of the number of target sequences until a large number, say, a million copies, of the target are generated. At that point detectable probes, e.g., radioactively labeled probes, can be used to detect the amplified number of targets.
  • RNA polymerase is used to make copies of the replicatable RNA.
  • replication of the RNA may take place while the RNA is linked to the probe. Alternatively, the replicatable RNA may be separated from the remainder of the probe prior to replication.
  • Nonspecifically bound probes will lead to replication just as will probes hybridized to targets.
  • the smart probe comprises a probe portion consisting of about 75-150 deoxynucleotides, made by in vitro or in vivo methods known in the art.
  • the smart probe also comprises a recombinant, replicatable RNA containing an inserted heterologous sequence of about 10-30 nucleotides, made by, e.g., the method of Miele, E.A., Mills, D.R., and Kramer, F.R., Autocatalytic Replication of a Recombinant RNA. J. Mol. Biol. 171:281-295 (1983).
  • Joining those two portions at their 5' ends is a linking moiety of the formula -0(P0 2 )NH(CH2) a SS(CH2)bNH(P0 2 )0- , where a and b are each 2 to 20. Furthermore, the sequence at the 3' end of the DNA portion of the smart probe is capable of being (and very likely to be) hybridized to the heterologous sequence of the RNA portion of the smart probe.
  • the enzyme ribonuclease H is said to be capable of cleaving the RNA portion of smart probes which have not hybridized to targets, but not be capable of cleaving the RNA portion of smart probes which have hybridized to targets, because when the probe sequence in the DNA portion of a smart probe is bound to its target, it is said to be incapable of also being hybridized to the heterologous sequence in the RNA portion of the smart probe, thereby providing a way to eliminate nonspecifically bound probes prior to amplification.
  • Amplification via RNA replication is said to optionally include the preliminary step of cleaving the disulfide bond in the linking moiety.
  • cleavage of probes not hybridized to targets is said to be possible for ribonuclease H, because the 3' end of the DNA portion of- the smart probe (which contains the probe sequence) is hybridized to the recombinant replicatable RNA portion, presumably thereby providing a site-wherein ribonuclease H can cleave the RNA and render it inoperative as a template for amplification by an RNA-directed RNA polymerase.
  • the probe portion comprises not only a probe segment of 50-150 nucleotides, but also additional segments, called “clamp” segments, on either side of it, that is, a 5'-clamp segment and a 3'-clamp segment, each of about 30-60 nucleotides.
  • Each clamp segment is said to hybridize with a segment of the replicatable RNA portion, rendering the RNA inactive as a template for replication, unless and until the probe is hybridized with a target. That hybridization causes the clamps to release, thereby rendering the RNA replicatable, either directly or after optional cleavage of the disulfide bond.
  • the smart probes disclosed in published European Patent Application No. 266,399 comprise a somewhat complicated linking moiety containing a weakly covalent and rather easily dissociable disulfide linkage. Disulfide bonds readily dissociate under reducing conditions.
  • the two versions of smart probes disclosed in that application rely on distant intramolecular interactions to render the probe smart. This is a disadvantage which makes such probes difficult to design, particularly since distant interactions are not well understood.
  • the second version, reported above, has a further complication that it utilizes two distant clamps which must displace a set of relatively strong neighboring compliments. And, the design depends on both distant clamps hybridizing or none,- which makes design very difficult.
  • the present invention is predicated on a simple molecular allosteric switch that works on the principle that when a nucleic acid double helix is formed between a relatively short probe sequence and a target sequence, the ends of the double helix are necessarily located at a distance from each other due to the rigidity of the double helix. That rigidity is discussed in detail in Shore, D. , Langowski, J. and Baldwin, R.L., DNA Flexibility Studied by Covalent Closure of Short Fragments into Circles, Proc. Natl. Sci. USA 18:4833-4837 (1981) ; and Ulanovsky, L. , Bodner, M. , Trifonov, E.N., and Choder, M. , Curved DNA: Design, Synthesis, and Circularization, Proc. .Natl. Acad. Sci. USA 83:862-866 (1986).
  • a nucleic acid hybridization probe comprising at least the following essentials: a probe sequence of approximately 15-115 nucleotides in length surrounded on both sides by complementary nucleic acid sequences which are considerably shorter than the probe sequence, preferably not greatly in excess of one-half the length of the probe sequence.
  • This combination of three sequences forms a simple molecular allosteric switch.
  • the switch sequences are hybridized to each other, which we refer to as a closed switch.
  • the probe sequence hybridizes to a predetermined complementary target sequence for which the probe is designed, the strong interaction between the probe and target sequences to form a rigid double helix necessarily results in the dissociation of the switch sequences, which we refer to as an open switch. In the open configuration, the switch sequences are unable to interact with each other.
  • the invention comprises probe molecules containing the above switch wherein one of the switch sequences, or both switch sequences in combination, comprise a biologically functional nucleic acid moiety useful for selectively generating a detectable signal indicative of the hybridization of the probe with its predetermined target sequence.
  • the invention further comprises bioassay methods which take advantage of the allosteric change in the switch sequences in the above probe molecules to generate a detectable signal indicative of the hybridization of the probe with its predetermined target sequence.
  • the assay may be qualitative (a qualitative demonstration) or quantitative (a quantitative determination) . It may include amplification, which may be linear or exponential in nature.
  • the invention also includes kits of reagents and macromolecules for carrying out the above bioassays.
  • Figure 1 is a schematic representation of a closed switch according to the invention.
  • Figure 2 is a schematic representation of the switch of Figure 1, but in an open state.
  • Figure 3 is a schematic representation of the probe of Example I, containing a switch in an open state.
  • Figure 4 is a schematic representation of the probe of Example II, containing a switch in an closed state.
  • Figure 6 is a schematic representation of the probe of Example III, containing a switch in an closed state.
  • Figure 7 is a schematic representation of the probe of Example III, containing a switch in an open state.
  • Figure 8 is a schematic representation of the probe of Example IV, containing a switch in an closed state.
  • Figure 9 is a schematic representation of the probe of Example IV, containing a switch in an open state and additionally showing a ribozyme.
  • Figure 10 is a detailed schematic showing the nucleotide sequences of the ribozyme shown in Figure 9.
  • Figure 11 is a schematic representation of the probe of Example IV, containing a switch in an open state and additionally showing an additional strand.
  • Figure 12 is a schematic representation of the probe of Example V, containing a switch in an closed state.
  • Figure 13 is a schematic representation of the probe of Example V, containing a switch in an open state.
  • FIG. 1 Shown in Figure 1 is a probe, or probe portion, comprising the three essential ingredients of a probe according to this invention, namely, a probe sequence and complementary switch sequences on both sides of the probe. As depicted in Figure 1, the switch is closed.
  • Figure 2 is the same probe or probe portion in its open state.
  • probe sequence 1 is a nucleic acid probe sequence extending from its 5' side 2 to its 3' side 3. Immediately adjacent to the 5' side of the probe sequence is a nucleic acid first switch sequence 4. Immediately adjacent to the 3' side of the probe sequence is a nucleic acid second switch sequence 5.
  • Switch sequences 4 and 5 are complementary and hybridize to each other via hydrogen bonds 7, forming the stem 6 of a "hairpin" secondary structure.
  • probe sequence 1 is hybridized via hydrogen bonds 9 to its predetermined target sequence 8. Switch sequences 4 and 5 are apart and not interacting with one another.
  • the probe may be RNA or DNA.
  • 1 must be of sufficient length to ensure a very specific interaction with its predetermined target sequence 8. It should be at least about 15 nucleotides in length, although we prefer that it be at least about 20 nucleotides in length.
  • the probe sequence 1 should be short enough to ensure that the sides 2, 3 of probe sequence 1, when hybridized to the target sequence 8 (Fig. 2) are physically prevented by the rigidity of the hybridized region between sides 2 and 3 from approaching each other within a distance that would permit switch sequences 4, 5 from interacting with each other. In other words, when the probe sequence is hybridized, the switch sequences necessarily are not hybridized to each other.
  • An additional force helps to drive the transition to an open state, namely, torsional forces tending to unwind stem 6 when the hybridized region shown in Figure 2 forms a double helix.
  • the probe sequence is no longer than about 100 nucleotides. We prefer that the probe sequence be 20- 60 nucleotides in length, and most preferably, about 30 nucleotides in length.
  • the switch sequences are related to the length of the probe sequence. Most preferably, we prefer that the length of the switch sequences be no more than half the length of the probe sequence.
  • the switch sequences should be at least about 10 nucleotides in length to permit formation of a stable stem 6. Turner, D.H. , Sugimoto, N. , Jaeger, J.A. , Longfellow, C.E., Freier, S.M. and Kierzek, R. , Improved
  • switch sequences for certain embodiments described below must also be sufficiently long to contain necessary functional sequences. We prefer switch sequences of about 10-30 nucleotides.
  • switch sequences must be adjacent to the probe sequence, they need not be immediately adjacent to it. A few nucleotides may separate the switch sequences from the probe sequences, but not so many that the functioning of the switch is materially affected, as those skilled in the art will readily appreciate.
  • Probe molecules of this invention containing the switch described above, can be of diverse design and still take advantage of the allosteric change that accompanies probe sequence hybridization (Fig. 2) in signal generation.
  • a switch sequence may, by virtue of the conformation it assumes in the open state, enable an interaction with another macromolecule, or even a different portion of the same molecule, which is required for the generation of a detectable signal.
  • the second switch sequence in the open state, is able to hybridize with a complementary nucleic acid strand.
  • the first switch sequence in the open state, forms a hairpin structure that enables it to bind specifically to a viral protein.
  • the second switch sequence in the open state, is able to interact with an oligoribonucleotide or with an oligodeoxyribo- nucleotide.
  • Example V the first switch sequence, in the open state, assumes a structured conformation that enables it to interact with a relatively distant region of the same probe molecule. It is also possible to do the reverse.
  • the switch sequences can bind to a specific enzyme only when they are in the closed state. Signal generation using probe molecules and methods of this invention may vary widely. The state of the simple allosteric switch governs signal generation, which means that there is no signal generated unless the probe sequence hybridizes with its target sequence. We prefer signal generating systems that involve amplification, particularly exponential amplification,- to increase sensitivity.
  • Detectable signals are diverse and include, for example, radiation, light absorption, fluorescence, mass increase, and the presence of biologically active compounds.
  • each of the specific embodiments set forth in the accompanying Examples satisfies the objective of generating a signal only if the probe is hybridized to a target sequence.
  • Either the biological activity of the signal generating systems illustrated depends strictly on the state of the switch, or the state of the switch provides a means for rendering nonspec ⁇ ifically bound probes unable to generate signals, or the state of the switch provides a means for separating hybridized probes from nonspecifically bound probes.
  • each of the specific embodiments markedly reduces the background caused by nonspec ⁇ ifically bound probes, thereby significantly improving the sensitivity of the assays, including assays which include amplification.
  • the switch sequences comprise the ends of the probe molecule.
  • the design of promoter and promoter-complement sequences is according to Osterman, H.L. and Coleman, J.E., "T7 Ribonucleic Acid Polymerase-Promoter Interactions," Biochemistry 2J):4885-4892 (1981) .
  • the particular promoter-complement sequence we have chosen to work ith is TAATACGACTCACTATA.
  • the target sequence must be exposed to the probe. This is done by techniques well known to the art. Commonly, but not necessarily, nucleic acid is isolated from a sample before the probe is added. The probe and the sample, which may contain nucleic acid target sequences, are next incubated under conditions, including time and temperature, appropriate to cause hybridization of probe sequences with target sequences. Appropriate conditions are well known in the art. For quantitative determination of the number of target sequences present, an amount of probe in excess, preferably in substantial excess, of the highest anticipated target amount should be used. If only a qualitative demonstration of the presence of target sequence ' s is desired, a lesser amount of probe can be used. Probes hybridized to targets are separated from unbound probes by methods well known to the art, for example, through the use of capture probes.
  • the treated sample will contain probes hybridized to targets (Fig. 2) and also nonspecifically bound probes.
  • targets Fig. 2
  • the allosteric switches are open; that is, the switch sequences are not hybridized to each other.
  • the switch sequences remain hybridized to each other.
  • This example includes amplification prior to detection.
  • the sample is incubated with a single-stranded DNA molecule 10 comprising a promoter sequence 11 and a template sequence 12 for the transcription of a replicatable RNA.
  • the promoter sequence 11 allows hybridization via hydrogen bonds 13, under conditions known to the art, to the promoter-complement of the second switch sequence 5 of probes having open switches.
  • this DNA molecule consists of the 17 deoxyribonucleotides of the promoter sequence (complementary to the promoter-complement set forth above) followed by the 244 deoxyribonucleotides complementary to MDV-poly
  • This DNA molecule can be prepared by isolating one of the complementary strands of a suitable restriction fragment of a plasmid containing that sequence by methods known in the art. Maniatis, T. , Fritsch, E.F., and Sanbrook, J. , MOLECULAR CLONING: A LABORATORY MANUAL Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982) .
  • the suitable plasmid that we constructed contained (1) a unique restriction site (that is, one contained nowhere else in the plasmid) upstream from and close to the promoter, and (2) and Sma I restriction site at the end of the MDV-poly cDNA sequence distal to the promoter.
  • the sample is incubated with commercially available cloned bacteriophage T7 RNA polymerase in order to synthesize about 50-200, or more, MDV-poly RNA transcripts for each open switch, using conditions known to the art.
  • Q-beta replicase an RNA-directed RNA polymerase
  • MDV-poly RNA transcripts which are templates for that polymerase.
  • Q-beta replicase by the method of Eoyang, L. , and August, J.T., Q-beta RNA polymerase from phage Q-beta-infected E. coli. pp. 829-839. In: Procedures in Nucleic Acid Research. Volume 2. (Cantoni, G.L., and Davis, D.R. , eds.). Harper and Row, New York (1971) . Incubation is carried out under conditions suitable for exponential amplification of the transcripts. Kramer, F.R. , Mills, D.R., Cole, P.E., Nishihara, T. , and
  • RNA-directed RNA polymerase Detection of the exponentially amplified RNA can be done by any of a variety of physical and chemical means, as described earlier in this application.
  • the amount of RNA detected after a fixed time of incubation with the RNA-directed RNA polymerase is a measure of the number of target sequence present in the sample.
  • the probe is a replicatable recombinant RNA 14.
  • the heterologous sequence 15 contained within the replicatable recombinant RNA is designed to contain three sequences: a probe sequence 16 approximately 46 nucleotides in length; a first switch sequence 17 of about 23 nucleotides immediately adjacent to the 5' side of the probe sequence; and a second switch sequence 18 of about 23 nucleotides immediately adjacent to the 3' side of the probe sequence.
  • the switch sequences are designed to form a double- stranded recognition site for Escherichia coli ribonuclease III when hybridized to each other.
  • This recognition site will not be present when the switch sequences are not hybridized to each other.
  • the particular recognition site we use is shown in Figure 4 and is described by Rosenberg, M. and Kramer, R.A. , Nucleotide Sequence Surrounding a Ribonuclease III Processing Site in Bacteriophage T7 RNA, Proc. Natl. Acad. Sci. USA 7_4:984-988 (1977). It can be made by transcription from a recombinant plasmid utilizing techniques described in Lizardi et al., supra.
  • the sample is then incubated with E. coli ribonuclease III under appropriate conditions known to the art to cleave all the nonspecifically bound probes (and any unbound probes which may remain) , rendering them unable to serve as templates for exponential replication by Q-beta replicase.
  • E. coli ribonuclease III is then removed from the sample by methods, e.g., phenol extraction, well known in the art.
  • the bacteriophage R17 coat protein is covalently linked to a solid support, such as, for example, Sephadex or Sepharoic beads, magnetic beads, or microtiter plates, by methods well known in the art.
  • a solid support such as, for example, Sephadex or Sepharoic beads, magnetic beads, or microtiter plates.
  • An example of such a method of linkage is described in Alagon, A.J., and King, T.P., Activation of
  • the probe 23 is a single strand of RNA designed to contain four functionally distinct sequences: a probe sequence 24 approximately 34 nucleotides in length; a first switch sequence 25 of about 17 nucleotides immediately adjacent to the 5' side of the probe sequence; a second switch sequence 26 complementary to, and of the same length as, the first and located immediately adjacent to the 3' side of the probe sequence; and a replicatable RNA sequence 27 extending from the 3' side of the second switch sequence, wherein at least five nucleotides of said replicatable RNA sequence are also nucleotides of the 3' side of the second switch sequence; that is, the replicatable RNA sequence can be considered to overlap the second switch sequence.
  • Ribozymes are structured RNA molecules that are capable of catalyzing a chemical reaction, such as particularly the cleavage of a phosphodiester bond. It is well known in the art that a ribozyme can be constructed by the interaction of two separate oligribonucleotides, one of which is cleaved at a particular phosphodiester bond when incubated under known, appropriate conditions. Uhlenbeck, O.C., A Small Catalytic Oligoribonucleotide, Nature 328:590- 600 (1987); Haseloff, J. and Gerlach, W.L. , Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities, Nature 334:585-591 (1988) .
  • the second switch sequence includes the required GUC sequence needed for cleavage of the phosphodister bond on the 3' side of the GUC sequence, that is, on the 5' side of the replicatable RNA sequence.
  • care is taken to ensure that the subsequent hybridization to form the ribozyme will be_more likely to occur than the interaction that can occur between the sides of the replicatable RNA sequence.
  • the probe can be made by transcription from a suitable recombinant plasmid.
  • a suitable recombinant plasmid is designed utilizing methods known to the art with the criteria of Lizardi et al., supra. It is constructed by methods well known to the art. Maniatis, T., Fritsch, E.F., and Sambrook, J., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982) .
  • the non-cleaved strand 28, which is capable of forming the required ribozyme, is also shown in Figure 9. It is made by ⁇ methods well known to the art. Milligan, J.F., Duncan, R.G., Witherell, G.W. and Uhlenbeck, O.C., Oligoribonucleotide Synthesis Using T7 RNA Polymerase and Synthetic DNA Templates, Nucleic Acids Research 15:8783-8798 (1987).
  • Figure 10 shows the nucleotide sequences of the ribozyme formed by switch sequence 26 and strand 28 of Figure 9.
  • the non-cleaved strand 28 described above is incubated with the sample under conditions, known to the art, that will promote hybridization of that strand with the second switch sequence in probes hybridized to target sequences to form the desired ribozyme. Incubation under known conditions referred to above cleaves the replicatable RNA from those probes and permits replicatable RNA to serve as a template for exponential replication by Q-beta replicase. Referring to Figure 10, - cleavage occurs in strand 26 between the sixth and seventh nucleotides from the left as shown in the figure. Exponential replication and detection proceed as described in Example I.
  • the probe 30 (Fig. 12) is a single-stranded RNA, prepared as described in Example IV but designed to contain five sequences: a probe sequence 31 approximately 34 nucleotides .in length; a first switch sequence 32 of about 17 nucleotides having the sequence of the non-cleaved strand 28 shown in Figure 9; a second switch sequence 33 of about 17 nucleotides complementary to the first sequence, as in Example I; a spacer sequence 34 of approximately 45 nucleotides extending from the 3' side of the second switch sequence, and a replicatable RNA moiety 35.
  • the six nucleotides at the 3' side of the spacer sequence are identical to the six nucleotides at the 5' side of the second switch sequence shown in Figure 9.
  • the region in which the spacer sequence is joined to the replicatable RNA sequence comprises the cleavable strand of a ribozyme, just as does the second switch sequence 26 in Example IV-A.
  • the first switch sequence 32 is hybridized to the second switch sequence 33.
  • the first switch sequence 32 is available to hybridize with the region in which the 3' side of the spacer sequence 34 is joined to the 5' side of the replicatable RNA sequence 35, thereby forming a ribozyme.
  • the spacer 34 is designed to be long enough to permit that hybridization.
  • the assays of this invention may be qualitative or quantitative. As one skilled in the art will readily appreciate, for a qualitative demonstration of a predetermined target sequence by the methods described above, biological and chemical reagents used in the assays must be used in readily determinable quantities sufficient to generate a reproducible, detectable signal in a sensitive assay.
  • the amount of probe added should be substantially in excess of the highest amount of target sequence expected and incubation should be carried out under conditions such that virtually all target sequences hybridize with probes.
  • virtual all we mean a very high percentage sufficient to impart reproducibility to the assay.
  • each step should be similarly quantitative. For example, destruction of unbound probes should destroy virtually all of the unbound probes for reproducibility and also to eliminate background noise.
  • Transcription and replication steps should utilize sufficient reagents to be quantitative and should be carried out for set times for the sake of reproducibility.
  • both qualitative and quantitative assays will include parallel assays of at least a negative control, that is, one not containing target sequence, and at times will also include a series of samples containing known amounts of target sequence, such as a geometrically increasing series.
  • the present invention is also directed to assay kits useful for the qualitative detection or quantitative determination of at least one specific, predetermined nucleic acid target sequence using probe molecules of this invention.
  • Assay kits will include quantities of one or more probes which comprise at least the three essential sequences described above and at least one additional biologically active molecule, for example, a DNA strand, a ribozyme former,- an- RNA_strand, or an enzyme, useful for generating a signal indicative of switch opening.
  • Kits may also include additional reagents such wash solutions, insolubilizing reagents and materials, amplification reagents and detection reagents.
  • Amplification reagents may include enzymes and nucleotides.
  • Detection reagents may include labeled nucleotides and color-forming substrates.
  • Kits designed for research may include plasmids which will enable a researcher to prepare probes according to this invention containing any desired probe sequence.

Abstract

A probe for the detection of a nucleic acid target sequence containing a molecular switch comprising three essential elements: a probe sequence of 20-60 nucleotides surrounded by switch sequences of 10-40 nucleotides which are complementary to each other, wherein the state of the switch is useful for selectively generating a detectable signal if the probe is hybridized to a target; also, assays and kits utilizing such probes.

Description

- r
NUCLEIC ACID PROBES CONTAINING IMPROVED MOLECULAR SWITCH. AND ASSAYS AND KITS INCORPORATING SAME
This invention relates to the field of bioassays that involve nucleic acid hybridization probes. These bioassays are useful for the detection of specific genes, gene segments or RNA molecules. The assays are useful clinically, for, e.g., tissue, blood and urine samples, as well as in food technology, agriculture, and biological research.
Background of the Invention
The use of nucleic acid hybridization probes for bioassays is well known. One of the early papers in the field directed to assays for DNA is Gillespie, D. and Spiegel an, S., A Quantitative Assay for DNA-RNA Hybrids with DNA Immobilized on a Membrane, J. Mol. Biol. 22:829-842 (1965). In general terms such an assay involves separating the nucleic acid polymer chains in a sample, as by melting, fixing the separated DNA strands to a nitrocellulose membrane, and then introducing a probe sequence which is complementary to a unique sequence of the material being sought, the "target" material, and incubating to hybridize probe segments to complementary target segments, if targets are present. Non-hybridized probes are removed by known washing techniques, and - then the amount of probe remaining is determined by one of a variety of techniques outlined below which provides a measurement of the amount of targets in the sample.
A more recently developed form of bioassay that uses nucleic acid hybridization probes involves a second probe, often called a "capture probe." Ranki, M. , Palva, A. , Virtanen M. , Laaksonen, M. , and Soderlund, H. , Sandwich Hybridization as a Convenient Method for the Detection of Nucleic Acids in Crude Samples, Gene 21:77-85 (1983); Syvanen, A.-C,
Laaksonen, M. , and Soderlund, H. , Fast Quantification of Nucleic Acid Hybrids by Affinity-based Hybrid Collection, Nucleic Acids Res. 14.:5037-5048 (1986) . A capture probe contains a nucleic acid sequence which is complementary to the target, preferably in a region near the sequence to which the radioactively labeled probe is complementary. The capture probe is provided with a means to bind it to a solid surface. Thus,' hybridization can be carried out in solution, where it occurs rapidly, and the hybrids can then be bound to a solid surface. One example of such a means is biotin. Langer, P.R. , Waldrop, A. . and Ward, D.C., Enzymatic Synthesis of Biotin-Labeled Polynucleotides: Novel Nucleic Acid Affinity Probes, Proc. Natl. Acad. Sci. USA 78:6633-6637 (1981). Through biotin the capture probe can be bound to streptavidin covalently linked to solid beads.
The present invention is directed to the methods and means, including assays and pharmaceutical kits containing requisite reagents and means, for detecting in an in vitro or ex vitro setting the presence of nucleic acid species.
It is a goal in this art to detect various nucleic acid sequences in a biological sample, in which the said sequences, as so-called target sequences, are present in small amounts relative to its existence amongst a wide variety of other nucleic acid species including RNA, DNA or both. Thus, it is desirable to detect the nucleic acid encoding polypeptides that may be associated with pathological diseases or conditions, such as, for example, RNA of the human immunodeficiency virus. In addition to the detection of nucleic acids encoding the proteins of such viral particles, it is desirable to detect other nucleic acids characteristic of a pathological disease or condition such as a defective gene, as in the case of_hemophilia. It is also desirable to detect other nucleic acids whose presence in the sample indicates that the organism is able to resist the action of a drug, such as an antibiotic.
Several approaches have been used for detecting the probe. One is to link a readily detectable reporter group to the probe. Examples of such reporter groups are fluorescent organic molecules and 32P-labeled phosphate groups. These detection techniques have a practical limit of sensitivity of about a million targets per sample.
A second approach is to link a signal generating system to the probe. Examples are enzymes such as peroxidase. Probes are then incubated with a color- forming substrate. Leary, J.J. , Brigati, D.J. and Ward, D.C., Rapid and Sensitive Colorimetric Method for Visualizing Biotin-Labeled DNA Probes Hybridized' to DNA or RNA Immobilized on Nitrocellulose: Bio- Blots, Proc. Natl. Acad. Sci. USA 80:4045-4049 (1983). Such amplification reduces the minimum number of target molecules which can be detected. As a . practical matter, however, nonspecific binding of probes has limited the improvement in sensitivity as compared to radioactive tagging to roughly an order of magnitude, i.e., to a minimum of roughly 100,000 target molecules.
Yet another approach is to make many copies of the target itself by in vivo methods. Hartley, J.L., Berninger, M. , Jessee, J.A. , Bloom, F.R. and Temple, G.S., Bioassay for Specific DNA Sequences Using a Non-Radioactive Probe, Gene 49:295-302 (1986). This can also be done in vitro using a technique called • "polymerase chain reaction" (PCR) . This technique was reported in Saiki, R.K. , Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T. , Erlich, H.A. , and Arnheim, N. , Enzymatic Amplification of Beta-globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia, Science 230:1350-1354 (1985); Saiki, R.K. , Gelfand, D.H. Stoffel, S., Scharf, S.J. , Higuchi, R. , Horn, G.T. , Mullis, K.B., and Erlich, H. A. , Primer-directed Enzymatic Amplification of DNA With a Thermostable DNA Polymerase, Science 239:487- 491 (1988); Erlich, H.A. , Gelfand, D.H. , and Saiki, R.K. , Specific DNA Amplification, Nature 331:461-462
(1988), and Mullis et al., European Patent Application Publication Nos. 200362 and 201184 (see also U.S. Patents 4,683,195 and 4,683,202). In PCR, the probe is complementary only to the beginning of a target sequence but, through an enzymatic process, serves as a primer for replication of an entire target. Each repetition of the process results in another doubling of the number of target sequences until a large number, say, a million copies, of the target are generated. At that point detectable probes, e.g., radioactively labeled probes, can be used to detect the amplified number of targets. The sensitivity of this method of target amplification is generally limited by the number of "false positive signals" generated, that is, generated segments that are not true copies of the target. Nonetheless, this method is quite sensitive. The procedure requires at least two nucleic acid probes and has three steps for a single cycle. This procedure is cumbersome and not always reliable.
Yet another method for amplification is to link to the probe an RNA that is known to be copied in an exponential fashion by an RNA-directed RNA polymerase. An example of such a polymerase is bacteriophage Q- beta replicase. Haruna, I., and Spiegel an, S., Autocatalytic Synthesis of a Viral RNA In Vitro. Science 150:884-886 (1965). Anotherexample is brome mosaic virus replicase. March et al., POSITIVE STRAND RNA VIRUSES Alan R. Liss, New York (1987) . In this technique, the RNA serves as a template for the exponential synthesis of RNA copies by a homologous RNA-directed RNA polymerase. The amount of RNA synthesized is much greater than the amount present initially. This amplification technique is disclosed in Chu, B.C.F., Kramer, F.R. , and Orgel, L.E., Synthesis of an Amplifiable Reporter RNA for Bioassays, Nucleic Acids Res. .14.:5591-5603 (1986) ; Lizardi, P.M., Guerra, C.E. , Lomeli, H. , Tussie-Luna, I. and Kramer, F.R., Exponential Amplification of Recombinant-RNA Hybridization Probes, Bio/Technology 6.:1197-1203 (October 1988), which is incorporated herein by reference and is attached hereto in manuscript form [hereinafter referred to as "Lizardi et al."]; published European Patent Application 266,399 (EP Application No. 87903131.8). After non- hybridized probes are removed by washing, the RNA polymerase is used to make copies of the replicatable RNA. According to the disclosure of published European Patent Application No. 266,399, replication of the RNA may take place while the RNA is linked to the probe. Alternatively, the replicatable RNA may be separated from the remainder of the probe prior to replication. That application also discloses a variety of chemical links by which a probe sequence can be joined to a replicatable RNA. In addition, it discloses that the probe sequence may be part of a replicatable RNA, as described in Miele, E.A. , Mills, D.R. , and Kramer, F.R. , Autocatalytic Replication of a Recombinant RNA, J. Mol. Biol. 171:281-295 (1983). That European application also discloses that such recombinant RNAs must be able to hybridize specifically with the target sequence as well as to retain their ability to serve as a template for exponential replication by an appropriate RNA-directed RNA polymerase, as is demonstrated in the results obtained by Lizardi et al., supra.
Replication of RNA, as opposed to target amplification using PCR, can be done in a single step. In that step one can synthesize as many as a billion copies of the replicatable RNA that was joined to the probe in as little as twenty minutes, which theoretically could lead to detection of a single target molecule. However, in practice the sensitivity of this type of probe replication is limited by the persistence of nonspecifically bound probes.
Nonspecifically bound probes will lead to replication just as will probes hybridized to targets.
A major problem in the implementation of bioassays that employ hybridization technology coupled to signal amplification systems is the background signal produced by nonspecifically bound probe molecules. These background signals introduce an artificial limit on the sensitivity of bioassays. In conventional bioassays this problem is sometimes alleviated by the utilization of elaborate washing schemes that are designed to remove nonspecifically bound probes. These washing schemes inevitably add to the complexity and cost of the assay.
As a means to reduce the background noise level of assays employing probes linked to replicatable RNA by covalently joined linking moieties, European Patent Application No. 266,399 discloses what it refers to as "smart probes," that is, probes whose linked RNA is said not to serve as a template for replication unless and until the probe has hybridized with a target sequence. In that application two embodiments are disclosed for smart probes.
In a first embodiment in- that application, the smart probe comprises a probe portion consisting of about 75-150 deoxynucleotides, made by in vitro or in vivo methods known in the art. The smart probe also comprises a recombinant, replicatable RNA containing an inserted heterologous sequence of about 10-30 nucleotides, made by, e.g., the method of Miele, E.A., Mills, D.R., and Kramer, F.R., Autocatalytic Replication of a Recombinant RNA. J. Mol. Biol. 171:281-295 (1983). Joining those two portions at their 5' ends is a linking moiety of the formula -0(P02)NH(CH2)aSS(CH2)bNH(P02)0- , where a and b are each 2 to 20. Furthermore, the sequence at the 3' end of the DNA portion of the smart probe is capable of being (and very likely to be) hybridized to the heterologous sequence of the RNA portion of the smart probe. The enzyme ribonuclease H is said to be capable of cleaving the RNA portion of smart probes which have not hybridized to targets, but not be capable of cleaving the RNA portion of smart probes which have hybridized to targets, because when the probe sequence in the DNA portion of a smart probe is bound to its target, it is said to be incapable of also being hybridized to the heterologous sequence in the RNA portion of the smart probe, thereby providing a way to eliminate nonspecifically bound probes prior to amplification. Amplification via RNA replication is said to optionally include the preliminary step of cleaving the disulfide bond in the linking moiety.
In that embodiment, cleavage of probes not hybridized to targets is said to be possible for ribonuclease H, because the 3' end of the DNA portion of- the smart probe (which contains the probe sequence) is hybridized to the recombinant replicatable RNA portion, presumably thereby providing a site-wherein ribonuclease H can cleave the RNA and render it inoperative as a template for amplification by an RNA-directed RNA polymerase.
In the other embodiment of a smart probe disclosed in published European Patent Application 266,399, there is a probe portion, a linking moiety, and a replicatable RNA portion, linked as described above. Here, however, the probe portion comprises not only a probe segment of 50-150 nucleotides, but also additional segments, called "clamp" segments, on either side of it, that is, a 5'-clamp segment and a 3'-clamp segment, each of about 30-60 nucleotides. Each clamp segment is said to hybridize with a segment of the replicatable RNA portion, rendering the RNA inactive as a template for replication, unless and until the probe is hybridized with a target. That hybridization causes the clamps to release, thereby rendering the RNA replicatable, either directly or after optional cleavage of the disulfide bond.
The smart probes disclosed in published European Patent Application No. 266,399 comprise a somewhat complicated linking moiety containing a weakly covalent and rather easily dissociable disulfide linkage. Disulfide bonds readily dissociate under reducing conditions. The two versions of smart probes disclosed in that application rely on distant intramolecular interactions to render the probe smart. This is a disadvantage which makes such probes difficult to design, particularly since distant interactions are not well understood. The second version, reported above, has a further complication that it utilizes two distant clamps which must displace a set of relatively strong neighboring compliments. And, the design depends on both distant clamps hybridizing or none,- which makes design very difficult.
An object of the present invention is a simple molecular allosteric switch that renders a nucleic acid hybridization probe smart, that is, capable, in an appropriate assay, of generating a signal only if the probe is hybridized to a target sequence.
It is a further object of this invention to couple the activity of a signal generating system to the state of such a switch.
It is yet another object of this invention to develop probes containing such an allosteric switch that are linked to any of a number of different signal generating systems whose activity is dependent on the state of the switch.
It is another object of this invention to develop assays of improved sensitivity that utilize the above constructs, as well as kits for performing such assays.
Summary of the Invention
The present invention is predicated on a simple molecular allosteric switch that works on the principle that when a nucleic acid double helix is formed between a relatively short probe sequence and a target sequence, the ends of the double helix are necessarily located at a distance from each other due to the rigidity of the double helix. That rigidity is discussed in detail in Shore, D. , Langowski, J. and Baldwin, R.L., DNA Flexibility Studied by Covalent Closure of Short Fragments into Circles, Proc. Natl. Sci. USA 18:4833-4837 (1981) ; and Ulanovsky, L. , Bodner, M. , Trifonov, E.N., and Choder, M. , Curved DNA: Design, Synthesis, and Circularization, Proc. .Natl. Acad. Sci. USA 83:862-866 (1986).
This invention involves the use of a nucleic acid hybridization probe comprising at least the following essentials: a probe sequence of approximately 15-115 nucleotides in length surrounded on both sides by complementary nucleic acid sequences which are considerably shorter than the probe sequence, preferably not greatly in excess of one-half the length of the probe sequence. This combination of three sequences forms a simple molecular allosteric switch. When not hybridized to a target sequence, the switch sequences are hybridized to each other, which we refer to as a closed switch. When the probe sequence hybridizes to a predetermined complementary target sequence for which the probe is designed, the strong interaction between the probe and target sequences to form a rigid double helix necessarily results in the dissociation of the switch sequences, which we refer to as an open switch. In the open configuration, the switch sequences are unable to interact with each other.
The invention comprises probe molecules containing the above switch wherein one of the switch sequences, or both switch sequences in combination, comprise a biologically functional nucleic acid moiety useful for selectively generating a detectable signal indicative of the hybridization of the probe with its predetermined target sequence. The invention further comprises bioassay methods which take advantage of the allosteric change in the switch sequences in the above probe molecules to generate a detectable signal indicative of the hybridization of the probe with its predetermined target sequence. The assay may be qualitative (a qualitative demonstration) or quantitative (a quantitative determination) . It may include amplification, which may be linear or exponential in nature. The invention also includes kits of reagents and macromolecules for carrying out the above bioassays.
Brief Description of the Drawings
Figure 1 is a schematic representation of a closed switch according to the invention. Figure 2 is a schematic representation of the switch of Figure 1, but in an open state.
Figure 3 is a schematic representation of the probe of Example I, containing a switch in an open state. Figure 4 is a schematic representation of the probe of Example II, containing a switch in an closed state.
Figure 5 is a schematic representation of the probe of Example II, containing a switch in an open state.
Figure 6 is a schematic representation of the probe of Example III, containing a switch in an closed state. Figure 7 is a schematic representation of the probe of Example III, containing a switch in an open state.
Figure 8 is a schematic representation of the probe of Example IV, containing a switch in an closed state.
Figure 9 is a schematic representation of the probe of Example IV, containing a switch in an open state and additionally showing a ribozyme. Figure 10 is a detailed schematic showing the nucleotide sequences of the ribozyme shown in Figure 9.
Figure 11 is a schematic representation of the probe of Example IV, containing a switch in an open state and additionally showing an additional strand. Figure 12 is a schematic representation of the probe of Example V, containing a switch in an closed state.
Figure 13 is a schematic representation of the probe of Example V, containing a switch in an open state.
Detailed Description of the Invention
Shown in Figure 1 is a probe, or probe portion, comprising the three essential ingredients of a probe according to this invention, namely, a probe sequence and complementary switch sequences on both sides of the probe. As depicted in Figure 1, the switch is closed. Figure 2 is the same probe or probe portion in its open state. Referring to Figure 1, probe sequence 1 is a nucleic acid probe sequence extending from its 5' side 2 to its 3' side 3. Immediately adjacent to the 5' side of the probe sequence is a nucleic acid first switch sequence 4. Immediately adjacent to the 3' side of the probe sequence is a nucleic acid second switch sequence 5. Switch sequences 4 and 5 are complementary and hybridize to each other via hydrogen bonds 7, forming the stem 6 of a "hairpin" secondary structure. Referring to Figure 2, probe sequence 1 is hybridized via hydrogen bonds 9 to its predetermined target sequence 8. Switch sequences 4 and 5 are apart and not interacting with one another. The probe may be RNA or DNA. The probe sequence
1 must be of sufficient length to ensure a very specific interaction with its predetermined target sequence 8. It should be at least about 15 nucleotides in length, although we prefer that it be at least about 20 nucleotides in length.
The probe sequence 1 should be short enough to ensure that the sides 2, 3 of probe sequence 1, when hybridized to the target sequence 8 (Fig. 2) are physically prevented by the rigidity of the hybridized region between sides 2 and 3 from approaching each other within a distance that would permit switch sequences 4, 5 from interacting with each other. In other words, when the probe sequence is hybridized, the switch sequences necessarily are not hybridized to each other. An additional force helps to drive the transition to an open state, namely, torsional forces tending to unwind stem 6 when the hybridized region shown in Figure 2 forms a double helix. In practice, the probe sequence is no longer than about 100 nucleotides. We prefer that the probe sequence be 20- 60 nucleotides in length, and most preferably, about 30 nucleotides in length.
The switch sequences are related to the length of the probe sequence. Most preferably, we prefer that the length of the switch sequences be no more than half the length of the probe sequence. The switch sequences should be at least about 10 nucleotides in length to permit formation of a stable stem 6. Turner, D.H. , Sugimoto, N. , Jaeger, J.A. , Longfellow, C.E., Freier, S.M. and Kierzek, R. , Improved
Parameters for Prediction of RNA Structure, Cold Spring Harbor Svmp. Quant. Biol. 52:123-133 (1987). The length of switch sequences for certain embodiments described below must also be sufficiently long to contain necessary functional sequences. We prefer switch sequences of about 10-30 nucleotides.
In designing a probe according to the invention, attention should be paid to the relative strengths of the open switch hybrid (Fig. 2) as compared to the closed switch hybrid (Fig. 1) under the assay conditions to be used: the former should be greater. There are assay conditions, however, in which the strengths of hybrids is only length-dependent. Wood, W.I., Gitschier, J. , Lasky, L.A. , and Lawn, R.M. , Base Composition-independent Hybridization in Tetramethylammonium Chloride: A Method for Oligonucleotide Screening of Highly Complex Gene Libraries, Proc. Natl. Acad. Sci. USA 82:1585-1588 (1985) . Switch design can be readily tested by digesting probes or probe portions (Figs. 1, 2) with appropriate nucleases before and after hybridization to model nucleic acids containing target sequences and then analyzing the digestion products by polyacrylamide gel electrophoresis. This will be apparent to those skilled in the art and will not be described further.
To help drive the transition from closed to open, one may take advantage of the principle of strand displacement to provide an additional force. Green, C. , and Tibbetts, C. , Reassociation Rate Limited Displacement of DNA Strands by Branch Migration, Nucleic Acids Res. 9:1905-1918 (1981). This may be accomplished by overlapping a switch sequence with a probe sequence, which means that at least one nucleotide of the switch sequence is also a nucleotide of the probe sequence.
While the switch sequences must be adjacent to the probe sequence, they need not be immediately adjacent to it. A few nucleotides may separate the switch sequences from the probe sequences, but not so many that the functioning of the switch is materially affected, as those skilled in the art will readily appreciate.
Probe molecules of this invention, containing the switch described above, can be of diverse design and still take advantage of the allosteric change that accompanies probe sequence hybridization (Fig. 2) in signal generation.
For example, a switch sequence may, by virtue of the conformation it assumes in the open state, enable an interaction with another macromolecule, or even a different portion of the same molecule, which is required for the generation of a detectable signal. In Example I below, the second switch sequence, in the open state, is able to hybridize with a complementary nucleic acid strand. In Example III, the first switch sequence, in the open state, forms a hairpin structure that enables it to bind specifically to a viral protein. In Example IV, the second switch sequence, in the open state, is able to interact with an oligoribonucleotide or with an oligodeoxyribo- nucleotide. In Example V, the first switch sequence, in the open state, assumes a structured conformation that enables it to interact with a relatively distant region of the same probe molecule. It is also possible to do the reverse. In Example II, the switch sequences can bind to a specific enzyme only when they are in the closed state. Signal generation using probe molecules and methods of this invention may vary widely. The state of the simple allosteric switch governs signal generation, which means that there is no signal generated unless the probe sequence hybridizes with its target sequence. We prefer signal generating systems that involve amplification, particularly exponential amplification,- to increase sensitivity.
The Examples which follow illustrate a few of the myriad variations involving amplification. They all utilize the exponential replication of a replicatable RNA by an RNA-directed RNA polymerase to generate a readily detectable signal. The Examples utilize MDV- 1 RNA, which is described in Kacian, D.L. , Mills, D..R. , Kramer, F.R. , and Spiegelman, S., A Replicating RNA Molecule Suitable for a Detailed Analysis of
Extracellular Evolution and Replication, Proc. Nat. Acad. Sci. USA 69:3038-3042 (1972). The Examples also use Q-beta replicase, which is the specific polymerase for replicating MDV-1 RNA. Q-beta replicase is described in Haruna, I. and Spiegelman, S., Specific Template Requirements of RNA Replicases, Proc. Nat. Acad. Sci. USA 54:579-587 (1965). Any replicatable RNA and its homologous replicase could, of course, be used. Other useful signal generating systems could employ enzymes, enzyme cofactors, ribozymes, DNA and RNA sequences required for biological activity (e.g., promoters, primers, or linkers required for the ligation of plasmids used to transform bacteria) . Detectable signals are diverse and include, for example, radiation, light absorption, fluorescence, mass increase, and the presence of biologically active compounds.
Assay techniques which can be used to detect hybridized probes of this invention are also diverse. In the following Examples, synthesis of a replicatable RNA is used to signal that hybridization of the probe sequence has occurred. The signal generating systems illustrated in the Examples fall into three broad classes: in Examples II-III, the switch is incorporated within a replicatable RNA; in Examples IV-V, a replicatable RNA sequence is joined with a probe portion but can only be replicated after cleavage, which is dependent upon the presence of an open switch; and in Example I, the transcription of a replicatable RNA from a template added after hybridization, can only occur when an open switch sequence forms a part of a functional promoter of transcription.
Each of the specific embodiments set forth in the accompanying Examples satisfies the objective of generating a signal only if the probe is hybridized to a target sequence. Either the biological activity of the signal generating systems illustrated depends strictly on the state of the switch, or the state of the switch provides a means for rendering nonspec¬ ifically bound probes unable to generate signals, or the state of the switch provides a means for separating hybridized probes from nonspecifically bound probes. Thus, each of the specific embodiments markedly reduces the background caused by nonspec¬ ifically bound probes, thereby significantly improving the sensitivity of the assays, including assays which include amplification. Example I
In this example, the probe is a single DNA strand designed to contain three sequences: a probe sequence approximately 34 nucleotides in length; a first switch sequence of about 17 nucleotides immediately adjacent to the 5' side of the probe sequence; and a second switch sequence of about 17 nucleotides immediately adjacent to the 3' side of the probe sequence. The switch sequences are designed to be complementary to one another. When hybridized to each other, the hybridized switch sequences comprise a promoter for the DNA-directed RNA polymerase, bacteriophage T7 RNA polymerase. In this application, we refer to the first switch sequence as a "promoter sequence" and the second switch sequence as a "promoter-complement" sequence. In this example, the switch sequences comprise the ends of the probe molecule. The design of promoter and promoter-complement sequences is according to Osterman, H.L. and Coleman, J.E., "T7 Ribonucleic Acid Polymerase-Promoter Interactions," Biochemistry 2J):4885-4892 (1981) . The particular promoter-complement sequence we have chosen to work ith is TAATACGACTCACTATA.
The probe molecule, including a probe sequence complementary to a predetermined target sequence, can be made by chemical synthesis of oligodeoxyribo- nucleotides using methods well known in the art, e.g.. Gait, M.J. , OLIGONUCLEOTIDE SYNTHESIS, IRL Press, Oxford, United Kingdom (1984) . The probe of this example can be used to detect a DNA or RNA target sequence which is complementary to the probe sequence. The target sequence may be in a sample containing other, unrelated nucleic acids and other materials, for example, proteins. The probe may be used to detect a gene segment of an infectious agent (virus, bacterium, protozoan, etc.) in a clinical sample of, for example, human blood or urine. The target sequence must be exposed to the probe. This is done by techniques well known to the art. Commonly, but not necessarily, nucleic acid is isolated from a sample before the probe is added. The probe and the sample, which may contain nucleic acid target sequences, are next incubated under conditions, including time and temperature, appropriate to cause hybridization of probe sequences with target sequences. Appropriate conditions are well known in the art. For quantitative determination of the number of target sequences present, an amount of probe in excess, preferably in substantial excess, of the highest anticipated target amount should be used. If only a qualitative demonstration of the presence of target sequence's is desired, a lesser amount of probe can be used. Probes hybridized to targets are separated from unbound probes by methods well known to the art, for example, through the use of capture probes.
After separation, the treated sample will contain probes hybridized to targets (Fig. 2) and also nonspecifically bound probes. The two are not in the same form, however. In the hybridized probes the allosteric switches are open; that is, the switch sequences are not hybridized to each other. In the nonspecifically bound probes, however, the switch sequences remain hybridized to each other.
Detecting those probes with open switches will now be described. This example includes amplification prior to detection.
Referring to Figure 3, the sample is incubated with a single-stranded DNA molecule 10 comprising a promoter sequence 11 and a template sequence 12 for the transcription of a replicatable RNA. The promoter sequence 11 allows hybridization via hydrogen bonds 13, under conditions known to the art, to the promoter-complement of the second switch sequence 5 of probes having open switches. Specifically, this DNA molecule consists of the 17 deoxyribonucleotides of the promoter sequence (complementary to the promoter-complement set forth above) followed by the 244 deoxyribonucleotides complementary to MDV-poly
(+) RNA described in Lizardi et al., supra. This DNA molecule can be prepared by isolating one of the complementary strands of a suitable restriction fragment of a plasmid containing that sequence by methods known in the art. Maniatis, T. , Fritsch, E.F., and Sanbrook, J. , MOLECULAR CLONING: A LABORATORY MANUAL Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982) . The suitable plasmid that we constructed contained (1) a unique restriction site (that is, one contained nowhere else in the plasmid) upstream from and close to the promoter, and (2) and Sma I restriction site at the end of the MDV-poly cDNA sequence distal to the promoter. Subsequently, the sample is incubated with commercially available cloned bacteriophage T7 RNA polymerase in order to synthesize about 50-200, or more, MDV-poly RNA transcripts for each open switch, using conditions known to the art. Milligan, J.F., Duncan, R.G., Witherell, G.W. and Uhlenbeck, O.C,
Oligoribonucleotide Synthesis Using T7 RNA Polymerase and Synthetic DNA Templates, Nucleic Acids Research 15.:8783-8798 (1987).
Then, Q-beta replicase, an RNA-directed RNA polymerase, is added and incubated with the MDV-poly RNA transcripts, which are templates for that polymerase. We prepared Q-beta replicase by the method of Eoyang, L. , and August, J.T., Q-beta RNA polymerase from phage Q-beta-infected E. coli. pp. 829-839. In: Procedures in Nucleic Acid Research. Volume 2. (Cantoni, G.L., and Davis, D.R. , eds.). Harper and Row, New York (1971) . Incubation is carried out under conditions suitable for exponential amplification of the transcripts. Kramer, F.R. , Mills, D.R., Cole, P.E., Nishihara, T. , and
Spiegelman, S., Evolution in vitro: Sequence and Phenotype of a Mutant RNA Resistant to Ethidium Bromide. J. Mol. Biol. 89_:719-736 (1974).
Detection of the exponentially amplified RNA can be done by any of a variety of physical and chemical means, as described earlier in this application. For a quantitative determination, the amount of RNA detected after a fixed time of incubation with the RNA-directed RNA polymerase is a measure of the number of target sequence present in the sample.
Example II
Referring to Figure 4, in this example, the probe is a replicatable recombinant RNA 14. Miele, E.A., Mills, D.R. , and Kramer, F.R., Autocatalytic Replication of a Recombinant RNA, J. Mol. Biol.
171:281-295 (1983). It may be prepared according to- the method of Lizardi et al., supra. For purposes of preparing a probe according to this example, the heterologous sequence 15 contained within the replicatable recombinant RNA is designed to contain three sequences: a probe sequence 16 approximately 46 nucleotides in length; a first switch sequence 17 of about 23 nucleotides immediately adjacent to the 5' side of the probe sequence; and a second switch sequence 18 of about 23 nucleotides immediately adjacent to the 3' side of the probe sequence. The switch sequences are designed to form a double- stranded recognition site for Escherichia coli ribonuclease III when hybridized to each other. This recognition site will not be present when the switch sequences are not hybridized to each other. The particular recognition site we use is shown in Figure 4 and is described by Rosenberg, M. and Kramer, R.A. , Nucleotide Sequence Surrounding a Ribonuclease III Processing Site in Bacteriophage T7 RNA, Proc. Natl. Acad. Sci. USA 7_4:984-988 (1977). It can be made by transcription from a recombinant plasmid utilizing techniques described in Lizardi et al., supra.
Exposure of the target sequence, hybridization of the probe with the target sequence, and separation from unbound probes, are as described in Example I. As shown in Figure 5, probe sequence 16 of a hybridized probe 14 is hybridized to target sequence 8, thereby forcing apart switch sequences 17, 18.
The sample is then incubated with E. coli ribonuclease III under appropriate conditions known to the art to cleave all the nonspecifically bound probes (and any unbound probes which may remain) , rendering them unable to serve as templates for exponential replication by Q-beta replicase. Nishihara, T. , Mills, D.R. , and Kramer, F.R. , Localization of the Q-beta Replicase Recognition Site in MDV-1 RNA, J. Biochem. £3:669-674 (1983). The ribonuclease III is then removed from the sample by methods, e.g., phenol extraction, well known in the art.
We release the probe from the target sequence by a brief heating step, Lizardi et al. supra, although preliminary experiments have indicated that this step may be optional.
Exponential replication of the probe by Q-beta replicase and detection proceed as described in Example I.
Example III
In this example the probe 19 (Fig. 6) is a replicatable recombinant RNA as in Example II, except that the probe sequence 20 is about 38 nucleotides in length and that the complementary switch sequences 21, 22, of about 19 nucleotides, are designed such that when they are hybridized to one another they do not form a binding site for the coat protein of bacteriophage R17, but when not so hybridized, as shown in Figure 7, the first switch sequence 21 organizes so as to comprise a secondary structure which is a strong binding site for that coat protein. Carey, J. , Cameron, V., de Haseth, P.L. and Uhlenbeck, O.C., Sequence-Specific Interaction of R17 Coat Protein With Its Ribonucleic Acid Binding Site, Biochemistry 2.2.:2601-2610 (1983) .
Exposure of the target sequence, hybridization of the probe with the target sequence, and separation from unbound probes are as described in Example I. The bacteriophage R17 coat protein is covalently linked to a solid support, such as, for example, Sephadex or Sepharoic beads, magnetic beads, or microtiter plates, by methods well known in the art. An example of such a method of linkage is described in Alagon, A.J., and King, T.P., Activation of
Polysaccharides with 2-Iminothiolane and Its Uses, Biochemistry JL9.:4331-4345 (1980). The washed sample, containing probes bound to target sequences and nonspecifically bound probes, is added to the insolubilized R17 coat protein. Nonspecifically bound probes are removed by washing.
We release the probe from both the R17 coat protein and the target sequence by a brief heating step, and remove the solid support.
Exponential replication of the probe by Q-beta replicase and detection proceed as described in Example I.
Example IV
In this example, the probe 23 (Fig. 8) is a single strand of RNA designed to contain four functionally distinct sequences: a probe sequence 24 approximately 34 nucleotides in length; a first switch sequence 25 of about 17 nucleotides immediately adjacent to the 5' side of the probe sequence; a second switch sequence 26 complementary to, and of the same length as, the first and located immediately adjacent to the 3' side of the probe sequence; and a replicatable RNA sequence 27 extending from the 3' side of the second switch sequence, wherein at least five nucleotides of said replicatable RNA sequence are also nucleotides of the 3' side of the second switch sequence; that is, the replicatable RNA sequence can be considered to overlap the second switch sequence.
Exposure of the target sequence, hybridization of probes to target sequences and separation of unbound probes are performed under appropriate conditions known to the art, as in Example I. As shown in Figure 9, probe sequence 24 is hybridized to target sequence 8, and switch sequences 25, 26 are forced apart, thereby freeing replicatable RNA sequence 27. The replicatable RNA sequences of bound probes are, at this point, not subject to exponential replication by RNA polymerase even though the switches are open. The replicatable RNA sequences 27 must be cleaved at their 5' sides to render them subject to exponential replication. Nishihara, T. , Mills, D.R. , and Kramer, F.R., Localization of the Q-beta Replicase Recognition Site in MDV-1 RNA, J. Biochem. 9.3:669-674 (1983). There are two means, at least, to cleave the replicatable RNA sequences. One is ribozyme cleavage. Another is cleavage by ribonuclease H. We prefer the former, which will be described first.
A. Ribozyme Cleavage
Ribozymes are structured RNA molecules that are capable of catalyzing a chemical reaction, such as particularly the cleavage of a phosphodiester bond. It is well known in the art that a ribozyme can be constructed by the interaction of two separate oligribonucleotides, one of which is cleaved at a particular phosphodiester bond when incubated under known, appropriate conditions. Uhlenbeck, O.C., A Small Catalytic Oligoribonucleotide, Nature 328:590- 600 (1987); Haseloff, J. and Gerlach, W.L. , Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities, Nature 334:585-591 (1988) .
The requirements for the two segments of an active ribozyme are outlined in the two references cited above. For purposes of this invention, the second switch sequence of our probe is designed to satisfy the requirements of the sequence that is cleaved. The replicatable RNA sequence with which we have chosen to proceed is MDV-poly (+) RNA according to Lizardi et al. supra. Our preferred design is shown in Figure 8. As shown there, the second switch sequence is 17 nucleotides in length, and 11 nucleotides of the 5' side of the MDV-poly (+) RNA are also nucleotides of the 3' side of the second switch sequence. The second switch sequence includes the required GUC sequence needed for cleavage of the phosphodister bond on the 3' side of the GUC sequence, that is, on the 5' side of the replicatable RNA sequence. In designing the second switch sequence, care is taken to ensure that the subsequent hybridization to form the ribozyme will be_more likely to occur than the interaction that can occur between the sides of the replicatable RNA sequence. The probe can be made by transcription from a suitable recombinant plasmid. Such a plasmid is designed utilizing methods known to the art with the criteria of Lizardi et al., supra. It is constructed by methods well known to the art. Maniatis, T., Fritsch, E.F., and Sambrook, J., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982) .
The non-cleaved strand 28, which is capable of forming the required ribozyme, is also shown in Figure 9. It is made by^methods well known to the art. Milligan, J.F., Duncan, R.G., Witherell, G.W. and Uhlenbeck, O.C., Oligoribonucleotide Synthesis Using T7 RNA Polymerase and Synthetic DNA Templates, Nucleic Acids Research 15:8783-8798 (1987). Figure 10 shows the nucleotide sequences of the ribozyme formed by switch sequence 26 and strand 28 of Figure 9.
Following separation of unbound probes, which we prefer, the non-cleaved strand 28 described above is incubated with the sample under conditions, known to the art, that will promote hybridization of that strand with the second switch sequence in probes hybridized to target sequences to form the desired ribozyme. Incubation under known conditions referred to above cleaves the replicatable RNA from those probes and permits replicatable RNA to serve as a template for exponential replication by Q-beta replicase. Referring to Figure 10, - cleavage occurs in strand 26 between the sixth and seventh nucleotides from the left as shown in the figure. Exponential replication and detection proceed as described in Example I.
B. Ribonuclease H Cleavage
The probe for this embodiment may be identical to the probe shown in Figure 8 and described above. In this embodiment we use commercially available E___ coli ribonuclease H, which cleaves an RNA strand when it is hybridized to a short DNA. oligonucleotide within the hybridized region. Donis-Keller, H. , Site Specific Enzymatic Cleavage of RNA, Nucleic Acids Res. 7:179-192 (1979).
To take advantage of this, we synthesize a short DNA oligonucleotide 29 (Fig. 11) of about 12 nucleotides that will hybridize to the second switch sequence on both sides of the GUC sequence. Following separation of unbound probes, which we prefer, the short DNA oligonucleotide 29 is incubated with the sample under well known conditions that will promote its hybridization (Fig. 11) to the second switch sequence. Then the ribonuclease H is added to catalyze cleavage during an incubation under known conditions. (Donis-Keller, supra) . Exponential replication by Q-beta replicase and detection proceed as described in Example I. Example V
This example resembles Example IV-A except that the ribozyme sequences are both part of the probe. The probe 30 (Fig. 12) is a single-stranded RNA, prepared as described in Example IV but designed to contain five sequences: a probe sequence 31 approximately 34 nucleotides .in length; a first switch sequence 32 of about 17 nucleotides having the sequence of the non-cleaved strand 28 shown in Figure 9; a second switch sequence 33 of about 17 nucleotides complementary to the first sequence, as in Example I; a spacer sequence 34 of approximately 45 nucleotides extending from the 3' side of the second switch sequence, and a replicatable RNA moiety 35. The six nucleotides at the 3' side of the spacer sequence are identical to the six nucleotides at the 5' side of the second switch sequence shown in Figure 9. Thus, the region in which the spacer sequence is joined to the replicatable RNA sequence comprises the cleavable strand of a ribozyme, just as does the second switch sequence 26 in Example IV-A. In the unbound probe, the first switch sequence 32 is hybridized to the second switch sequence 33. - In probes hybridized to target sequences, where the switch is open, however, the first switch sequence 32 is available to hybridize with the region in which the 3' side of the spacer sequence 34 is joined to the 5' side of the replicatable RNA sequence 35, thereby forming a ribozyme. The spacer 34 is designed to be long enough to permit that hybridization.
Exposure of the target sequence, hybridizing of probes to target sequences, and separation of unbound probes, which we prefer, is as described in Example I. Upon hybridization of a probe to a target sequence (Fig. 13) , the switch sequences 32, 33 are not hybridized to each other and the ribozyme 36 is formed. Release of the replicatable RNA, exponential replication and detection proceed as in Example IV-A. As stated above the assays of this invention may be qualitative or quantitative. As one skilled in the art will readily appreciate, for a qualitative demonstration of a predetermined target sequence by the methods described above, biological and chemical reagents used in the assays must be used in readily determinable quantities sufficient to generate a reproducible, detectable signal in a sensitive assay. For a quantitative determination, the amount of probe added should be substantially in excess of the highest amount of target sequence expected and incubation should be carried out under conditions such that virtually all target sequences hybridize with probes. By "virtually all" we mean a very high percentage sufficient to impart reproducibility to the assay. In subsequent steps through signal detection, each step should be similarly quantitative. For example, destruction of unbound probes should destroy virtually all of the unbound probes for reproducibility and also to eliminate background noise. Transcription and replication steps should utilize sufficient reagents to be quantitative and should be carried out for set times for the sake of reproducibility.
Often, both qualitative and quantitative assays will include parallel assays of at least a negative control, that is, one not containing target sequence, and at times will also include a series of samples containing known amounts of target sequence, such as a geometrically increasing series.
The present invention is also directed to assay kits useful for the qualitative detection or quantitative determination of at least one specific, predetermined nucleic acid target sequence using probe molecules of this invention. Assay kits will include quantities of one or more probes which comprise at least the three essential sequences described above and at least one additional biologically active molecule, for example, a DNA strand, a ribozyme former,- an- RNA_strand, or an enzyme, useful for generating a signal indicative of switch opening. Kits may also include additional reagents such wash solutions, insolubilizing reagents and materials, amplification reagents and detection reagents. Amplification reagents may include enzymes and nucleotides. Detection reagents may include labeled nucleotides and color-forming substrates. Kits designed for research may include plasmids which will enable a researcher to prepare probes according to this invention containing any desired probe sequence.

Claims

WE CLAIM:
1. A probe for the detection of a predetermined nucleic acid target sequence comprising a. a probe sequence of from about 20 to about 60 nucleotides, having a 5' side and a 3' side, which probe sequence is complementary to said target sequence, b. a first switch sequence of from about 10 to about 40 nucleotides at the 5' side of the probe sequence, c. — a-second switch sequence of from about 10 to about 40 nucleotides at the 3' side of the probe sequence, said second switch sequence being complementary to said first switch sequence, wherein, when the probe sequence is not hybridized with said target sequence, the first switch sequence is hybridized to the second switch sequence but, when the probe sequence is hybridized with said target sequence, thereby forming a double helix, the rigidity of said double helix prevents the first switch sequence from hybridizing to the second switch sequence, and wherein said first switch sequence, said second switch sequence, or said first and second switch sequences in combination, comprise a biologically functional nucleic acid moiety useful for selectively generating a detectable signal if the probe sequence is hybridized with said target sequence.
2. A probe according to claim 1 wherein said probe sequence, said first switch sequence, and said second switch sequence are segments of a single nucleic acid strand.
3. A probe according to claim 1 wherein said first switch sequence and said second switch sequence are immediately adjacent to said probe sequence.
4. A probe according to claim 1 wherein at least one nucleotide of said first switch sequence is also a nucleotide of said probe sequence.
5. A probe according to claim 1 wherein at least one nucleotide of said second switch sequence is also a nucleotide of said probe sequence.
6. A probe according to claim 1 wherein said second switch sequence includes a promoter-complement sequence for a DNA-directed RNA polymerase.
7. A recombinant replicatable RNA containing a probe according to claim 1, wherein said first switch sequence and said second switch sequence, when hybridized to each other, result in an allosteric configuration which prevents replication of said RNA.
8. A probe according to claim 2, wherein one of said first and second switch sequences, when not hybridized to the other, comprises a biologically functional nucleic acid moiety which is a required element of a signal generating system.
9. A probe according to claim 8 wherein said single nucleic acid strand is a DNA strand and wherein said second switch sequence includes a promoter- complement sequence for a DNA-directed RNA polymerase.
10. A probe according to claim 8 wherein said single nucleic acid strand is a DNA strand and wherein said second switch sequence includes a primer for a DNA-directed DNA polymerase.
11. A probe according to claim 8 wherein said single nucleic acid strand is a DNA strand and wherein said second switch sequence includes a primer for a DNA-directed RNA polymerase.
12. A probe according to claim 2 additionally comprising a replicatable RNA sequence extending from said second switch sequence, said replicatable RNA sequence being able to serve as a template for exponential replication by an RNA polymerase only if cleaved from said probe.
13. A probe according to claim 12 wherein at least one nucleotide of said replicatable RNA sequence is also a nucleotide of said second switch sequence.
14. A probe according to claim 12 comprising a spacer sequence between said second switch sequence and said replicatable RNA sequence and joined to said replicatable RNA sequence, wherein said first switch sequence comprises a portion of a ribozyme, and wherein the spacer sequence and the replicatable RNA sequence in the area where they are joined together comprise the remainder of said ribozyme.
15. A probe according to claim 14 wherein said second switch sequence is unable to form a ribozyme with said first switch sequence.
16. A replicatable recombinant RNA molecule containing a probe according to claim 2.
17. A replicatable recombinant RNA molecule according to claim 16 wherein said first and second switch sequences, when hybridized to each other, comprise a binding site for a specific protein.
18. A replicatable recombinant RNA molecule according to claim 17 wherein the specific protein is a ribonuclease.
19. A replicatable recombinant RNA molecule according to claim 16 wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for a specific protein.
20. A replicatable recombinant RNA molecule according to claim 19 wherein said specific protein is a bacteriophage protein.
21. A recombinant replicatable RNA according to claim 19, wherein said cleavage site is a site for .cleavage by a restriction enzyme.
22. A recombinant replicatable RNA according to claim 21, wherein said restriction enzyme is ribonuclease III.
23. A probe according to claim 2 wherein said single nucleic acid strand is a DNA strand.
24. A probe according to claim 23 wherein said first and second switch sequences, when hybridized to each other, comprise a binding site for a specific protein.
25. A probe according to claim 23 wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for a specific protein.
26. A probe according to claim 23, wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for —a DNA sequence, required for signal generation.
27. A probe according to claim 23, wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for an RNA sequence required for signal generation.
28. A probe according to claim 2 wherein said single nucleic acid strand is an RNA strand.
29. A probe according to claim 28 wherein said first and second switch sequences, when hybridized to each other, comprise a binding site for a specific protein.
30. A probe according to claim 28 wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for a specific protein.
31. A probe according to claim 28 wherein one of said first and second switch sequences, when not hybridized to each other, comprises a binding site for an oligodeoxyribonucleotide.
32. A probe according to claim 28 wherein one of said first and second switch sequences, when not hybridized to the other, comprises a binding site for a DNA sequence required for signal generation.
33. A probe according to claim 32 wherein one of said first and second switch sequences, when not hybridized.to the other, comprises a binding site for an RNA sequence required for signal generation.
34. A probe according to claim 28, comprising an RNA sequence extending from and adjacent to a selected one of said first and second switch sequences, said RNA sequence and said selected switch sequence together comprising a binding site for a nucleic acid sequence necessary for signal generation.
35. A probe according to claim 34 wherein said nucleic acid sequence necessary for signal generation is an RNA.
36. A probe according to claim 35 wherein said binding site and said nucleic acid sequence necessary for signal generation, when hybridized, form a binding site for a protein.
37. A probe according to claim 35 wherein said binding site and said nucleic acid sequence necessary for signal generation, when hybridized, together comprise a ribozyme.
38. A probe according to claim 37 wherein said ribozyme cleaves from the probe an RNA probe fragment necessary for signal generation.
39. A probe according to claim 38 wherein said RNA probe fragment comprises a replicatable RNA.
40. A probe according to claim 38 wherein said RNA probe fragment comprises a linker.
41. A probe according to claim 38 wherein said
RNA probe fragment comprises a primer.
42. A probe according to claim 34 wherein said nucleic acid sequence necessary for signal generation is an oligodeoxyribonucleotide.
43. A probe according to claim 42 wherein said binding site and said nucleic acid sequence necessary for signal generation, when hybridized, form a protein binding site.
44. A probe according to claim 43 wherein said protein binding site is a binding site for ribonuclease H.
45. A probe according to claim 28 comprising an RNA sequence extending from a selected one of said first and second switch sequences and separated therefrom by a spacer sequence of about 30-70 nucleotides, said RNA sequence and said spacer sequence forming a binding site for the other switch sequence, such that, when hybridized, said binding site and said other switch sequence together comprise a ribozyme required for signal generation.
46. A probe according to claim 45 wherein said ribozyme cleaves from the probe an RNA probe fragment necessary for signal generation.
47. A probe according to claim 46 wherein said RNA probe fragment comprises a replicatable RNA.
48. A probe according to claim 46 wherein said RNA probe fragment comprises a linker.
49. A probe according to claim 46 wherein said RNA probe fragment comprises a primer.
50. A method for the detection of at least one predetermined nucleic acid target sequence in a sample containing nucleic acid and comprising the steps of a. adding to the sample probes according to claim 1, b. causing probes to hybridize specifically with said target sequence, c. destroying the ability of probes which did not hybridize specifically with said target sequence in step b to generate a signal. d. generating a signal from probes which did hybridize specifically with said target sequence in step b, and e. detecting the signal.
51. A method according to claim 50 wherein said probe is a replicatable RNA.
52. A method according to claim 51 wherein step c. comprises destroying with a ribonuclease the replicatability of probes which did not hybridize specifically with said target sequence and wherein step d. comprises exponentially replicating probes which did hybridize specifically with said target sequence.
53. A method according to claim 51 wherein probes hybridized specifically with said target sequence in step b. are separated from probes which did not so hybridize prior to performing step d.
54. A method according to claim 50 comprising a quantitative determination of the amount of said - -_ target sequence in said sample, wherein the amount of probe added in step a. substantially exceeds the maximum expected number of target sequences expected in said samples, wherein step b. proceeds until virtually all target sequences hybridize with probes, wherein in step c. the replicatability of virtually all of the probes which did not hybridize specifically with said target sequence is destroyed, wherein step d. is carried out for a predetermined time, and wherein step e. is quantitative.
55. A method according to claim 54 additionally comprising performing a parallel assay on a sample which does not contain said target sequence.
56. A method for the detection of at least one predetermined nucleic acid target sequence in a sample containing nucleic acid comprising the steps of a. adding to the sample probes according to claim 1, b. causing probes to hybridize specifically with said target sequence, c. exponentially replicating a replicatable
RNA indicative of the presence of probes which hybridized specifically with said target sequence in step b. , and d. detecting the replication products.
57. A method according to claim 56, wherein said probe is a first DNA strand, comprising the additional step of hybridizing to the second switch sequence of said probe a second DNA strand which is a template for the transcription of a replicatable RNA prior to step c.
58. A method according to claim 56, wherein said probe is a replicatable recombinant RNA, comprising the additional step of separating probes which hybridized with target sequence in step b. from probes which did not so hybridize prior to step c. , and wherein the replicatable RNA of step c. is said replicatable recombinant RNA.
59. A method according to claim 56 wherein said probe is an RNA strand comprising a replicatable RNA sequence extending from said second switch segment, comprising the additional step of selectively cleaving said replicatable RNA sequence from probes which hybridized with target sequences in step b. prior to step c. , and wherein the replicatable RNA of step c. is said replicatable RNA sequence.
60. A method according to claim 59 wherein the step of cleaving involves ribozyme cleavage.
61. A method according to claim 59 wherein the step of cleaving includes adding a ribonuclease to the sample.
62. A method according to claim 56 comprising a quantitative determination of the amount of said target sequence in said sample, wherein the amount of probe added in step a. substantially exceeds the maximum expected number of target sequences expected in said sample, wherein step b. proceeds until virtually all target sequences hybridize with probes, wherein step c. is carried out for a predetermined time, and wherein step d. is quantitative.
63. A method according to claim 62 additionally comprising performing a parallel assay on a sample which does not contain said target sequence.
64. A method for the detection of at least one predetermined nucleic acid target sequence in a sample containing nucleic acid comprising the steps of a. adding to the sample probes according to claim 1, b. causing probes to hybridize specifically with said target sequence, c. cleaving said RNA-signal generator segment from probes which hybridized with target sequences in step b. , d. generating an amplified signal using said RNA-signal generator, and e. detecting said amplified signal.
65. A method according to claim 64 wherein said RNA-signal generator includes an enzyme which generates a color signal.
66. A test kit for performing an assay according to claim 50 comprising a quantity of said probe and an appropriate RNA replicase.
67. A test kit for performing an assay according to claim 56 comprising a quantity of said probe and an appropriate RNA replicase.
PCT/US1989/004275 1988-09-30 1989-09-29 Nucleic acid probes containing improved molecular switch, and assays and kits incorporating same WO1990003446A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU43466/89A AU647376B2 (en) 1988-09-30 1989-09-29 Nucleic acid probes containing improved molecular switch, and assays and kits incorporating same
DE68926302T DE68926302T2 (en) 1988-09-30 1989-09-29 NUCLEIC ACID PROBES, WHICH CONTAIN IMPROVED MOLECULAR SWITCHES, AND ANALYSIS METHODS AND KITS, WHICH THE PROBE IS USED WITH
EP89911480A EP0436644B1 (en) 1988-09-30 1989-09-29 Nucleic acid probes containing an improved molecular switch; and assays and kits incorporating same
DK056091A DK56091A (en) 1988-09-30 1991-03-27 NUCLEIC ACID PROBLEMS CONTAINING AN IMPROVED MOLECULE CHANGE AND ANALYSIS AND KITS, WHICH ARE INCLUDED
FI911536A FI911536A0 (en) 1988-09-30 1991-03-28 NUCLEINSYRASONDER SOM INNEHAOLLER EN FOERBAETTRAD MOLEKYLOMKOPPLARE, SAMT BESTAEMNINGSFOERFARANDEN OCH TESTFOERPACKNINGAR INNEHAOLLANDE DEM.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/251,696 US5118801A (en) 1988-09-30 1988-09-30 Nucleic acid process containing improved molecular switch
US251,696 1988-09-30

Publications (1)

Publication Number Publication Date
WO1990003446A1 true WO1990003446A1 (en) 1990-04-05

Family

ID=22953028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004275 WO1990003446A1 (en) 1988-09-30 1989-09-29 Nucleic acid probes containing improved molecular switch, and assays and kits incorporating same

Country Status (10)

Country Link
US (2) US5118801A (en)
EP (1) EP0436644B1 (en)
JP (1) JP2806455B2 (en)
AT (1) ATE136941T1 (en)
AU (1) AU647376B2 (en)
DE (1) DE68926302T2 (en)
DK (1) DK56091A (en)
ES (1) ES2023290A6 (en)
FI (1) FI911536A0 (en)
WO (1) WO1990003446A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361983A2 (en) * 1988-09-30 1990-04-04 Amoco Corporation RNA template end-linked probe constructs and methods for use
EP0481704A1 (en) * 1990-10-16 1992-04-22 Ciba Corning Diagnostics Corp. Amplification of midivariant DNA templates
EP0552931A1 (en) * 1992-01-22 1993-07-28 Gen-Probe Incorporated Hybridization assay using branched nucleic acid probes
EP0601889A2 (en) * 1992-12-10 1994-06-15 Maine Medical Center Research Institute Nucleic acid probes
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0736103A1 (en) * 1993-12-17 1996-10-09 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
JPH09504950A (en) * 1993-11-12 1997-05-20 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク Hybridization probe for nucleic acid detection, common stem, method and kit
EP0851033A1 (en) * 1996-12-30 1998-07-01 Gen-Probe Incorporated Target-triggered amplification
US6177247B1 (en) 1994-02-01 2001-01-23 The Regents Of The University Of California Detection methods using probes labeled with energy transfer coupled dyes for DNA fragment analysis
US6485903B1 (en) 1995-05-05 2002-11-26 Pe Corporation (Ny) Methods and reagents for combined PCR amplification and hybridization probing
US6544744B1 (en) 1994-02-01 2003-04-08 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6821727B1 (en) 1993-11-15 2004-11-23 Applera Corporation Hybridization assay using self-quenching fluorescence probe
US6830902B1 (en) 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
WO2005073403A1 (en) * 2004-01-30 2005-08-11 Dade Behring Marburg Gmbh Test system and method for the detection of analytes
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7537886B1 (en) 1999-06-22 2009-05-26 Life Technologies Corporation Primers and methods for the detection and discrimination of nucleic acids
US7635598B2 (en) 2004-07-08 2009-12-22 Biosearch Technologies, Inc. Inducible fluorescence assay
US8466266B2 (en) 2008-04-01 2013-06-18 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
WO2013113748A1 (en) 2012-02-02 2013-08-08 Primer Design Ltd Method for detecting and genotyping target nucleic acid
US10041117B2 (en) 2001-10-23 2018-08-07 Life Technologies Corporation Primers and methods for the detection and discrimination of nucleic acids

Families Citing this family (348)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503975A (en) * 1989-03-01 1996-04-02 City Of Hope Mechanism based inhibitors of DNA methyltransferase
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6100024A (en) * 1991-02-08 2000-08-08 Promega Corporation Methods and compositions for nucleic acid detection by target extension and probe amplification
US5663318A (en) * 1991-03-01 1997-09-02 Pegg; Randall Kevin Assay preparation containing capture and detection polynucleotides covalently bound to substrates with a heterobifunctional crosslinking agent
CA2118518C (en) * 1991-08-30 2005-05-10 Atushi Ohshima Over expression of single-stranded molecules
US5780273A (en) * 1993-04-09 1998-07-14 Amoco Corporation Insertion elements and amplifiable nucleic acids
US6495676B1 (en) 1993-04-13 2002-12-17 Naxcor Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US6277570B1 (en) 1993-04-13 2001-08-21 Naxcor Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents
US6576419B1 (en) * 1993-07-23 2003-06-10 University Of Utah Research Foundation Assay procedure using fluorogenic tracers
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US20070160581A1 (en) * 1994-04-29 2007-07-12 Cytogenix, Inc. Production of ssDNA in vivo
US20070269799A9 (en) * 1994-06-22 2007-11-22 Zhang David Y Nucleic acid amplification methods
US6593086B2 (en) 1996-05-20 2003-07-15 Mount Sinai School Of Medicine Of New York University Nucleic acid amplification methods
USRE38442E1 (en) * 1994-06-22 2004-02-24 Mount Sinai School Of Medicine Nucleic acid amplification method hybridization signal amplification method (HSAM)
US5876924A (en) * 1994-06-22 1999-03-02 Mount Sinai School Of Medicine Nucleic acid amplification method hybridization signal amplification method (HSAM)
US5942391A (en) * 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
WO1996040992A2 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Probe masking method of reducing background in an amplification reaction
US6337183B1 (en) * 1995-09-08 2002-01-08 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for nucleic acids
CA2252048C (en) * 1996-04-12 2008-03-11 The Public Health Research Institute Of The City Of New York, Inc. Detection probes, kits and assays
US7070925B1 (en) 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5866336A (en) * 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6130038A (en) * 1996-07-16 2000-10-10 Gen-Probe Incorporated Method for amplifying target nucleic acids using modified primers
US6893868B2 (en) * 1997-02-20 2005-05-17 Onco Immunin, Inc. Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
US7312302B2 (en) 1997-02-20 2007-12-25 Oncolmmunin, Inc. Compositions for the detection of enzyme activity in biological samples and methods of use thereof
CA2282418A1 (en) 1997-03-05 1998-09-11 Scriptgen Pharmaceuticals, Inc. Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids
US7008765B1 (en) * 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
US6355421B1 (en) 1997-10-27 2002-03-12 Boston Probes, Inc. Methods, kits and compositions pertaining to PNA molecular beacons
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US6093545A (en) * 1997-12-04 2000-07-25 Millennium Pharmaceuticals, Inc. Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors
AU3909199A (en) 1997-12-15 1999-07-05 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
WO1999049293A2 (en) * 1998-03-24 1999-09-30 Boston Probes, Inc. Methods, kits and compositions pertaining to detection complexes
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
WO2000001850A2 (en) * 1998-07-02 2000-01-13 Gen-Probe Incorporated Molecular torches
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
ATE278035T1 (en) * 1999-05-04 2004-10-15 Ortho Clinical Diagnostics Inc FAST AND EFFECTIVE DNA IMMOBILIZATION FROM A SAMPLE WITHOUT THE USE OF CELL LYSIS REAGENTS
ES2459745T3 (en) * 1999-05-14 2014-05-12 Brandeis University Aptamer based detection
US6680377B1 (en) * 1999-05-14 2004-01-20 Brandeis University Nucleic acid-based detection
US6277607B1 (en) 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
US20070059752A1 (en) * 1999-06-09 2007-03-15 Biosearch Technologies, Inc. Fluorescence energy transfer probes with stabilized conformations
JP2003504641A (en) * 1999-07-19 2003-02-04 ザ アルゼクシス カンパニー インコーポレーティッド Thermochemical sensors and uses thereof
PT1222266E (en) * 1999-09-29 2006-07-31 Diagnocure Inc PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES
US7824859B2 (en) * 1999-10-29 2010-11-02 Cytyc Corporation Methods for detection of a target nucleic acid by forming a cleavage structure using an RNA polymerase
US7118860B2 (en) * 1999-10-29 2006-10-10 Stratagene California Methods for detection of a target nucleic acid by capture
US6893819B1 (en) * 2000-11-21 2005-05-17 Stratagene California Methods for detection of a nucleic acid by sequential amplification
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US7534568B2 (en) 1999-10-29 2009-05-19 Hologic Inc. Methods for detection of a target nucleic acid by forming a cleavage structure with a cleavage resistant probe
JP2004512813A (en) * 1999-11-29 2004-04-30 ガミダ センス ダイアグノスティックス リミテッド Oligonucleotides and assemblies thereof useful for detecting whether a target nucleic acid sequence is present in a sample
US6383784B1 (en) 1999-12-03 2002-05-07 City Of Hope Construction of nucleoprotein based assemblies comprising addressable components for nanoscale assembly and nanoprocessors
US20030065155A1 (en) * 2000-03-06 2003-04-03 Nassim Usman Nucleic acid sensor molecules
US20040009510A1 (en) * 2000-03-06 2004-01-15 Scott Seiwert Allosteric nucleic acid sensor molecules
US20040023292A1 (en) * 2001-10-19 2004-02-05 Mcswiggen James Method and reagent for the detection of proteins and peptides
US7262006B1 (en) 2000-05-01 2007-08-28 Ortho-Clinical Diagnostics, Inc. Rapid and efficient capture of DNA from sample without using cell lysing reagent
US6562575B1 (en) 2000-06-26 2003-05-13 Epicentre Technologies Corporation Analyte-specific assays based on formation of a replicase substrate
US6596490B2 (en) * 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
US6380377B1 (en) 2000-07-14 2002-04-30 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
JP4965793B2 (en) 2000-09-01 2012-07-04 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
US6350580B1 (en) * 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
NZ528348A (en) * 2001-02-27 2007-07-27 Virco Bvba Circular probe amplification (CPA) using closed circular padlock probe molecules and energy-transfer primers
FR2822234B1 (en) * 2001-03-14 2003-06-13 Univ Pasteur METHOD FOR LOCAL DETERMINATION OF STRUCTURAL PARAMETERS OF MOLECULES, ESPECIALLY BIOCHEMICAL OR PHARMACOLOGICAL AND USES OF SAID METHOD
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
EP1275735A1 (en) * 2001-07-11 2003-01-15 Roche Diagnostics GmbH Composition and method for hot start nucleic acid amplification
WO2003052116A2 (en) * 2001-07-17 2003-06-26 Stratagene Methods for detection of a target nucleic acid using multi-subunit probes
EP1288314B1 (en) * 2001-08-31 2006-08-09 The University of Utah Research Foundation Real-time gene quantification with internal standards
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
US7070933B2 (en) * 2001-09-28 2006-07-04 Gen-Probe Incorporated Inversion probes
US20040106109A1 (en) * 2001-10-02 2004-06-03 Belly Robert T Detection of ras mutations
US20030082563A1 (en) * 2001-10-15 2003-05-01 Bell Constance A. Detection of bacillus anthracis
DE10153829A1 (en) * 2001-11-05 2003-05-28 Bayer Ag Assay based on doped nanoparticles
US20030219775A1 (en) * 2001-12-14 2003-11-27 Ward David C. Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
US20030224435A1 (en) * 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
WO2003102239A2 (en) * 2002-05-31 2003-12-11 Secretary, Department Of Atomic Energy Met/fret based method of target nucleic acid detection whereby the donor/acceptor moieties are on complementary strands
AU2003253651C1 (en) 2002-06-14 2010-06-03 Gen-Probe Incorporated Compositions and methods for detecting hepatitis B virus
JP4384603B2 (en) 2002-06-26 2009-12-16 コールド スプリング ハーバー ラボラトリー Methods and compositions for measuring methylation profiles
US6896727B2 (en) * 2002-06-28 2005-05-24 Seh America, Inc. Method of determining nitrogen concentration within a wafer
US20040009574A1 (en) * 2002-07-09 2004-01-15 Nanibhushan Dattagupta Compositions and methods for detecting streptococcus agalactiae capsular polysaccharide synthesis genes
US20040009482A1 (en) * 2002-07-09 2004-01-15 Nanibhushan Dattagupta Compositions and methods for detecting streptococcus agalactiae surface immunogenic protein genes
US7582470B2 (en) * 2002-07-31 2009-09-01 Gen-Probe Incorporated Device for amplifying and detecting a target nucleic acid
US20060073475A1 (en) * 2002-08-09 2006-04-06 Nanibhushan Dattagupta Compositions and methods for detecting pathogenic bacteria expressing chaperonin proteins
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
JP4694201B2 (en) * 2002-09-20 2011-06-08 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Anthraquinone quenching dyes, their production and use
US20070184453A1 (en) * 2002-10-02 2007-08-09 Roche Molecular Systems, Inc Fret process
US7115374B2 (en) 2002-10-16 2006-10-03 Gen-Probe Incorporated Compositions and methods for detecting West Nile virus
US7718361B2 (en) * 2002-12-06 2010-05-18 Roche Molecular Systems, Inc. Quantitative test for bacterial pathogens
EP1426447A1 (en) * 2002-12-06 2004-06-09 Roche Diagnostics GmbH Method for the detection of pathogenic gram positive bacteria selected from the genera Staphylococcus, Enterococcus and Streptococcus
WO2004053155A1 (en) * 2002-12-06 2004-06-24 Roche Diagniostics Gmbh Multiplex assay detection of pathogenic organisms
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
US8206904B2 (en) 2002-12-18 2012-06-26 Third Wave Technologies, Inc. Detection of nucleic acids
CA2511012C (en) 2002-12-20 2018-02-27 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US6936496B2 (en) 2002-12-20 2005-08-30 Hewlett-Packard Development Company, L.P. Nanowire filament
WO2004069850A2 (en) * 2003-02-04 2004-08-19 Borer Philip N Switchable nucleic acids for diagnostics, screening and molecular electronics
ES2427853T3 (en) 2003-02-07 2013-11-04 Diagnocure Inc. Procedure to detect prostate cancer in a sample
US7741031B2 (en) * 2003-03-07 2010-06-22 The Public Health Research Institute Of The City Of New York Optically decodable microcarries, arrays and methods
FR2852317B1 (en) * 2003-03-13 2006-08-04 PROBE BIOPUCES AND METHODS OF USE
US20040191801A1 (en) * 2003-03-25 2004-09-30 Heeger Alan J. Reagentless, reusable bioelectronic detectors and their use as authentication devices
US8003374B2 (en) 2003-03-25 2011-08-23 The Regents Of The University Of California Reagentless, reusable, bioelectronic detectors
WO2004087950A2 (en) * 2003-04-04 2004-10-14 Roche Diagnostics Gmbh Improved system for multi color real time pcr
EP1625228A4 (en) * 2003-05-09 2007-05-02 Capitalbio Corp Methods and compositions for detecting sars virus
EP1644531A4 (en) * 2003-06-25 2009-03-11 Somagenics Inc Polynucleotides capable of target-dependent circularization and topological linkage
CN100494399C (en) * 2003-06-30 2009-06-03 清华大学 Genotype typing method based on DNA chip and use thereof
CN1860242B (en) * 2003-08-01 2013-11-06 戴诺生物技术有限公司 Self-hybridizing multiple target nucleic acid probes and methods of use
EP1502958A1 (en) * 2003-08-01 2005-02-02 Roche Diagnostics GmbH New detection format for hot start real time polymerase chain reaction
CN1580283A (en) * 2003-08-13 2005-02-16 清华大学 Method for detecting nucleic acid molecule
WO2005028647A1 (en) * 2003-09-22 2005-03-31 Kyoto University Nucleic acid probe, nucleic acid chip, method of detecting target nucleic acid, method of screening drug, apparatus for detecting target nucleic acid and gene diagnosis method
US7788039B2 (en) * 2003-09-25 2010-08-31 Roche Molecular Systems, Inc. Quantitation of nucleic acids using growth curves
US7132298B2 (en) * 2003-10-07 2006-11-07 Hewlett-Packard Development Company, L.P. Fabrication of nano-object array
US7223611B2 (en) * 2003-10-07 2007-05-29 Hewlett-Packard Development Company, L.P. Fabrication of nanowires
CA2542542C (en) 2003-10-21 2015-09-15 Orion Genomics Llc Method of detecting a quantity of methylation at a locus
WO2005049849A2 (en) * 2003-11-14 2005-06-02 Integrated Dna Technologies, Inc. Fluorescence quenching azo dyes, their methods of preparation and use
US7667024B2 (en) * 2003-11-19 2010-02-23 Allelogic Biosciences Corp. Oligonucleotides labeled with a plurality of fluorophores
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
CA2494571C (en) * 2003-12-02 2010-02-09 F.Hoffmann-La Roche Ag Oligonucleotides containing molecular rods
ATE478968T1 (en) 2003-12-19 2010-09-15 Gen Probe Inc COMPOSITIONS, METHODS AND KITS FOR DETECTING THE NUCLEIC ACIDS OF HIV-1 AND HIV-2
WO2005060618A2 (en) * 2003-12-19 2005-07-07 California Institute Of Technology Enzyme-free isothermal exponential amplification of nucleic acids and nucleic acid analog signals
KR100906749B1 (en) * 2004-03-25 2009-07-09 (주)바이오니아 Methods for Detecting Nucleic Acid Amplification Using Probe Labeled with Intercalating Dye
US7407738B2 (en) * 2004-04-02 2008-08-05 Pavel Kornilovich Fabrication and use of superlattice
US7466908B1 (en) 2004-04-16 2008-12-16 Spartan Bioscience Inc. System for rapid nucleic acid amplification and detection
US7247531B2 (en) 2004-04-30 2007-07-24 Hewlett-Packard Development Company, L.P. Field-effect-transistor multiplexing/demultiplexing architectures and methods of forming the same
US20050241959A1 (en) * 2004-04-30 2005-11-03 Kenneth Ward Chemical-sensing devices
US7683435B2 (en) 2004-04-30 2010-03-23 Hewlett-Packard Development Company, L.P. Misalignment-tolerant multiplexing/demultiplexing architectures
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
EP1745154B1 (en) 2004-05-07 2012-08-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
US7776530B2 (en) * 2004-06-29 2010-08-17 Wallac Oy Integrated nucleic acid analysis
ATE466107T1 (en) 2004-07-01 2010-05-15 Gen Probe Inc METHODS AND COMPOSITIONS FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE
US20060024814A1 (en) * 2004-07-29 2006-02-02 Peters Kevin F Aptamer-functionalized electrochemical sensors and methods of fabricating and using the same
EP1781825B1 (en) 2004-08-03 2011-09-28 Syracuse University Branched or multi-chain nucleic acid switches for detecting and screening
EP1634965B1 (en) 2004-09-09 2010-01-20 Roche Diagnostics GmbH Real time PCR with the addition of pyrophosphatase
US20060051796A1 (en) * 2004-09-09 2006-03-09 Inga Boell Real time PCR with the addition of pyrophosphatase
US20060068380A1 (en) 2004-09-30 2006-03-30 Gen-Probe Incorporated Assay for detecting and quantifying HIV-1
CA2582661C (en) * 2004-11-09 2015-08-11 Gen-Probe Incorporated Compositions and methods for detecting group a streptococci
US20060275792A1 (en) * 2004-11-15 2006-12-07 Lee Jun E Enhancement of nucleic acid amplification using double-stranded DNA binding proteins
US20060105348A1 (en) * 2004-11-15 2006-05-18 Lee Jun E Compositions and methods for the detection and discrimination of nucleic acids
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
EP2208796B1 (en) 2005-01-06 2014-06-18 Applied Biosystems, LLC Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
ATE357653T1 (en) * 2005-01-18 2007-04-15 Hoffmann La Roche FLUORESCENT IMAGING USING TELECENTRIC EXCITATION AND IMAGING OPTICS
ES2285578T3 (en) * 2005-01-18 2007-11-16 F. Hoffmann-La Roche Ag VISUALIZATION OF FLUORESCENCE SIGNS USING TELECENTRICITY.
AU2006212754B2 (en) * 2005-02-07 2009-09-03 Gen-Probe Incorporated Compositions and methods for detecting Group B Streptococci
ATE493494T1 (en) 2005-02-18 2011-01-15 Gen Probe Inc SAMPLE PREPARATION METHOD USING AN ALKALINE PUSH
US7375012B2 (en) * 2005-02-28 2008-05-20 Pavel Kornilovich Method of forming multilayer film
CA2599013A1 (en) * 2005-02-28 2006-09-08 Gen-Probe Incorporated Compositions and methods of detecting an analyte by using a nucleic acid hybridization switch probe
JP4398886B2 (en) * 2005-03-07 2010-01-13 ソニー株式会社 COMMUNICATION TERMINAL DEVICE, COMMUNICATION SYSTEM, COMMUNICATION METHOD, AND PROGRAM
US7727721B2 (en) 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
EP1700922B1 (en) 2005-03-10 2016-08-24 Roche Diagnostics GmbH 3-Substituted 5-Nitroindole derivatives and labeled oligonucleotide probes containing them
US7759469B2 (en) 2005-03-10 2010-07-20 Roche Diagnostics Operations, Inc. Labeling reagent
EP1856296A2 (en) 2005-03-11 2007-11-21 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
US7601498B2 (en) * 2005-03-17 2009-10-13 Biotium, Inc. Methods of using dyes in association with nucleic acid staining or detection and associated technology
US7776567B2 (en) 2005-03-17 2010-08-17 Biotium, Inc. Dimeric and trimeric nucleic acid dyes, and associated systems and methods
WO2006121773A2 (en) 2005-05-06 2006-11-16 Gen-Probe Incorporated Compositions and assays to detect influenza virus a and b nucleic acids
WO2006122401A1 (en) * 2005-05-16 2006-11-23 Institut De Recherches Cliniques De Montreal/I.R.C.M. Negative regulation of nk cell functions by eat-2, a sap-related adaptor expressed in innate immune cells
WO2006127507A2 (en) 2005-05-20 2006-11-30 Integrated Dna Technologies, Inc. Compounds and methods for labeling oligonucleotides
US8357801B2 (en) 2005-05-24 2013-01-22 Enzo Life Sciences, Inc. Labeling of target molecules, identification of organelles and other applications, novel compositions, methods and kits
US7569695B2 (en) * 2005-05-24 2009-08-04 Enzo Life Sciences, Inc. Dyes for the detection or quantification of desirable target molecules
US7737281B2 (en) * 2005-05-24 2010-06-15 Enzo Life Sciences, Inc. C/O Enzo Biochem, Inc. Purine based fluorescent dyes
US8362250B2 (en) 2005-05-24 2013-01-29 Enzo Biochem, Inc. Fluorescent dyes and compounds, methods and kits useful for identifying specific organelles and regions in cells of interest
EP1749892B1 (en) 2005-08-02 2008-03-19 Roche Diagnostics GmbH Nucleotide sequence for assessing TSE
US20070042408A1 (en) * 2005-08-02 2007-02-22 Michael Knoll Nucleotide sequence for assessing transmissible spongiform encephalopathies
US7569367B2 (en) 2005-09-07 2009-08-04 Roche Diagnostics Operations, Inc. Nucleic acid preparation from whole blood for use in diagnosis of transmissible spongiform encephalopathy
US20070059713A1 (en) * 2005-09-09 2007-03-15 Lee Jun E SSB-DNA polymerase fusion proteins
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2007044727A2 (en) 2005-10-07 2007-04-19 California Institute Of Technology Pkr activation via hybridization chain reaction
EP1937847A2 (en) 2005-10-17 2008-07-02 Gen-Probe Incorporated Compositions and methods to detect legionella pneumophila nucleic acid
US7781165B2 (en) 2005-10-19 2010-08-24 Roche Diagnostics Operations, Inc. Benzimidazolium compounds and salts of benzimidazolium compounds for nucleic acid amplification
EP1801114B8 (en) 2005-11-23 2009-12-02 Roche Diagnostics GmbH Polynucleotides with a phosphate mimetic
US7803542B2 (en) * 2005-11-29 2010-09-28 The Regents Of The University Of California Signal-on architecture for electronic, oligonucleotide-based detectors
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
CN101421417B (en) * 2006-02-27 2013-04-03 霍夫曼-拉罗奇有限公司 PCR hot start by magnesium sequestration
WO2007134208A2 (en) * 2006-05-12 2007-11-22 Gen-Probe Incorporated Compositions and methods to detect enterococci nucleic acid
WO2008002920A2 (en) * 2006-06-26 2008-01-03 Epoch Biosciences, Inc. Methods for generating target nucleic acid sequences
JP5635772B2 (en) 2006-08-01 2014-12-03 ジェン−プロウブ インコーポレイテッド Method for capturing non-specific target of nucleic acid
US7993833B2 (en) 2006-09-11 2011-08-09 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
CA2666346C (en) 2006-10-20 2016-02-23 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US9938641B2 (en) * 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
JP5340167B2 (en) 2006-12-21 2013-11-13 ジェン−プロウブ インコーポレイテッド Methods and compositions for nucleic acid amplification
EP2129789B1 (en) 2007-01-31 2013-03-06 Celera Corporation Method of determining risk associated with breast cancer metastasis by the determination of a molecular prognostic signature.
EP1978111B1 (en) 2007-04-02 2013-03-27 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of Pseudomonas aeruginosa
JP5191041B2 (en) 2007-04-05 2013-04-24 エフ.ホフマン−ラ ロシュ アーゲー Rapid one-step RT-PCR
US8043810B2 (en) * 2007-05-02 2011-10-25 Eagle Eye Research, Inc. Analyte detection using autocatalytic chain reactions
WO2008144562A1 (en) * 2007-05-16 2008-11-27 California Institute Of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
EP2527472B1 (en) 2007-05-31 2016-09-28 Yale University A genetic lesion associated with cancer
US8420315B2 (en) 2007-08-06 2013-04-16 Orion Genomics Llc Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
DE102007041864B4 (en) 2007-09-04 2012-05-03 Sirs-Lab Gmbh Method for the detection of bacteria and fungi
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US7595164B2 (en) * 2007-12-26 2009-09-29 Gen-Probe Incorporated Compositions and methods to detect Candida albicans nucleic acid
EP2238459B1 (en) * 2008-01-23 2019-05-08 Roche Diagnostics GmbH Integrated instrument performing synthesis and amplification
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
US8497364B2 (en) * 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
US20090253142A1 (en) * 2008-03-15 2009-10-08 Hologic, Inc. Compositions and methods for analysis of nucleic acid molecules during amplification reactions
CA2658520C (en) * 2008-03-19 2016-11-08 F. Hoffmann-La Roche Ag Nucleic acid amplification in the presence of modified randomers
EP2808405B1 (en) 2008-04-21 2018-06-06 Gen-Probe Incorporated Method for Detecting Chikungunya Virus
CA2723726C (en) 2008-05-13 2017-09-12 Michael M. Becker Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
US20100021904A1 (en) * 2008-05-21 2010-01-28 Pierce Niles A Shielded cross-linking probes
US20100021901A1 (en) * 2008-05-22 2010-01-28 Peng Yin Compositions and methods for detecting analytes
JP2011521651A (en) 2008-05-30 2011-07-28 ジェン−プロウブ インコーポレイテッド Compositions, kits and related methods for detection and / or monitoring of Salmonella
EP2878680B1 (en) 2008-07-09 2016-06-08 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
EP2148187A1 (en) 2008-07-25 2010-01-27 Roche Diagnostics GmbH Stimulation and optical display system for fluorescence detection
CA2638458A1 (en) * 2008-07-31 2010-01-31 Spartan Bioscience Inc. Thermal recycling by positioning relative to fixed-temperature source
WO2010012464A1 (en) * 2008-08-01 2010-02-04 Roche Diagnostics Gmbh Improved lysis and reverse transcription for mrna quantification
US9250249B2 (en) * 2008-09-08 2016-02-02 Enzo Biochem, Inc. Autophagy and phospholipidosis pathway assays
US9334281B2 (en) * 2008-09-08 2016-05-10 Enzo Life Sciences, Inc. Fluorochromes for organelle tracing and multi-color imaging
US7910720B2 (en) * 2008-09-09 2011-03-22 Roche Diagnostics Operations, Inc. Polyanion for improved nucleic acid amplification
CA2682439A1 (en) 2008-10-17 2010-04-17 F. Hoffmann-La Roche Ag Cell monitoring and molecular analysis
EP2367958B1 (en) 2008-11-25 2017-08-23 Gen-Probe Incorporated Compositions and methods for detecting small rnas, and uses thereof
CA2688174C (en) 2008-12-19 2018-08-07 F. Hoffmann-La Roche Ag Dry composition of reaction compounds with stabilized polymerase
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2910647A1 (en) 2008-12-30 2015-08-26 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of listeria
US20120028254A1 (en) 2009-02-06 2012-02-02 Weidhaas Joanne B SNP Marker of Breast and Ovarian Cancer Risk
EP2396429B1 (en) 2009-02-11 2015-05-27 Orion Genomics, LLC Combinations of polymorphisms for determining allele-specific expression of igf2
US9347092B2 (en) * 2009-02-25 2016-05-24 Roche Molecular System, Inc. Solid support for high-throughput nucleic acid analysis
JP5457222B2 (en) * 2009-02-25 2014-04-02 エフ.ホフマン−ラ ロシュ アーゲー Miniaturized high-throughput nucleic acid analysis
EP3118208A1 (en) 2009-02-26 2017-01-18 Gen-Probe Incorporated Assay for detection of human parvovirus nuleic acid
CA2768768C (en) 2009-06-23 2021-08-24 Gen-Probe Incorporated Compositions and methods for detecting nucleic acid from mollicutes
EP2446056A2 (en) 2009-06-25 2012-05-02 Yale University Single nucleotide polymorphisms in brca1 and cancer risk
US9169512B2 (en) 2009-07-01 2015-10-27 Gen-Probe Incorporated Methods and compositions for nucleic acid amplification
WO2011037802A2 (en) 2009-09-28 2011-03-31 Igor Kutyavin Methods and compositions for detection of nucleic acids based on stabilized oligonucleotide probe complexes
US9133343B2 (en) 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
CA2782692C (en) 2009-12-03 2021-11-09 Quest Diagnostics Investments Incorporated Methods for the diagnosis of bacterial vaginosis
US8877437B1 (en) 2009-12-23 2014-11-04 Biotium, Inc. Methods of using dyes in association with nucleic acid staining or detection
EP2536849B1 (en) 2010-02-17 2016-05-11 Gen-Probe Incorporated Compositions and methods to detect atopobium vaginae nucleic acid
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
EP2553123B1 (en) 2010-03-26 2016-08-24 Integrated DNA Technologies, Inc. Methods for enhancing nucleic acid hybridization
US20120108799A1 (en) 2010-09-07 2012-05-03 Integrated Dna Technologies, Inc. Modifications for Antisense Compounds
US20110250598A1 (en) 2010-04-12 2011-10-13 Ulrike Fischer Detergent free polymerases
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
WO2011133811A2 (en) 2010-04-21 2011-10-27 Gen-Probe Incorporated Compositions, methods and kits to detect herpes simplex virus nucleic acid
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
JP2013529089A (en) 2010-06-07 2013-07-18 エフ.ホフマン−ラ ロシュ アーゲー Gene expression markers for predicting response to drug treatment with monoclonal antibodies that inhibit interleukin-6 receptor
US9650629B2 (en) 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
EP3674423A1 (en) 2010-07-12 2020-07-01 Gen-Probe Incorporated Compositions and assays to detect seasonal h3 influenza a virus nucleic acid
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
EP2606150B1 (en) 2010-08-20 2016-03-16 Life Technologies Corporation Quantitative real-time pcr assay using fret dual-labeled primers
EP2611932A2 (en) 2010-08-30 2013-07-10 Gen-Probe Incorporated Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus
US8557532B2 (en) 2010-08-30 2013-10-15 The University Of Utah Research Foundation Diagnosis and treatment of drug-resistant Ewing'S sarcoma
US20120070829A1 (en) 2010-09-10 2012-03-22 Bio-Rad Laboratories, Inc. Size selection of dna for chromatin analysis
EP2625297B1 (en) 2010-10-04 2018-10-10 Gen-Probe Prodesse, Inc. Compositions, methods and kits to detect adenovirus nucleic acids
JP6174999B2 (en) 2010-10-04 2017-08-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Method for cell lysis in PCR reaction buffer
CN103124797B (en) 2010-10-04 2015-04-22 霍夫曼-拉罗奇有限公司 Method for cell lysis and PCR within the same reaction vessel
WO2012045668A1 (en) 2010-10-04 2012-04-12 Roche Diagnostics Gmbh Method for cell lysis in a rt-pcr reaction buffer
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
US20120208193A1 (en) 2011-02-15 2012-08-16 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic dna
EP2675914A1 (en) 2011-02-18 2013-12-25 Yale University, Inc. The kras-variant and endometriosis
WO2012122571A1 (en) 2011-03-10 2012-09-13 Gen-Probe Incorporated Methods and compositions for the selection and optimization of oligonucleotide tag sequences
US20140065615A1 (en) 2011-03-21 2014-03-06 Yale University The KRAS Variant and Tumor Biology
EP2702166B1 (en) 2011-04-25 2018-06-06 Gen-Probe Incorporated Compositions and methods for detecting bv-associated bacterial nucleic acid
EP3536809A1 (en) 2011-07-15 2019-09-11 Gen-Probe Incorporated Compositions and method for detecting human parvovirus nucleic acid
EP2753713B1 (en) 2011-09-08 2017-07-19 Gen-Probe Incorporated Compositions and methods for detecting bv-associated bacterial nucleic acid
WO2013041577A1 (en) 2011-09-20 2013-03-28 Vib Vzw Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration
AU2012312169B2 (en) 2011-09-21 2016-01-14 Gen-Probe Incorporated Methods for amplifying nucleic acid using tag-mediated displacement
US9416153B2 (en) 2011-10-11 2016-08-16 Enzo Life Sciences, Inc. Fluorescent dyes
DE102011120550B4 (en) 2011-12-05 2013-11-07 Gen-Probe Prodesse, Inc. Compositions, methods and kits for the detection of adenovirus nucleic acids
CA2865281C (en) 2012-02-24 2021-11-23 Gen-Probe Prodesse, Inc. Detection of shiga toxin genes in bacteria
US9932633B2 (en) 2012-03-21 2018-04-03 Roche Molecular Systems, Inc. Methods for assessing RNA quality
AU2013243300B2 (en) 2012-04-05 2018-12-06 Oregon Health & Science University Gene expression panel for breast cancer prognosis
US9562271B2 (en) 2012-04-20 2017-02-07 T2 Biosystems, Inc. Compositions and methods for detection of Candida species
AU2013205110B2 (en) 2012-04-24 2016-10-13 Gen-Probe Incorporated Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
AU2013205064B2 (en) 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
EP2850078B1 (en) 2012-08-28 2018-04-25 Pierce Biotechnology, Inc. Benzopyrylium compounds
ES2761920T3 (en) 2012-08-30 2020-05-21 Gen Probe Inc Multiphasic nucleic acid amplification
AU2013205122B2 (en) 2012-10-11 2016-11-10 Gen-Probe Incorporated Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
AU2013205090B2 (en) 2012-12-07 2016-07-28 Gen-Probe Incorporated Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid
CA2908266A1 (en) 2013-03-27 2014-10-02 Sample Technologies, Inc. Recombinant phage and bacterial detection methods
WO2014205221A2 (en) 2013-06-19 2014-12-24 Sample6 Technologies, Inc. Phage-based bacterial detection assay
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
CN105452488B (en) 2013-08-14 2020-07-14 简·探针公司 Compositions and methods for detecting HEV nucleic acids
WO2015085230A1 (en) 2013-12-06 2015-06-11 Bio-Rad Laboratories, Inc. Fusion polymerases
CA2940591C (en) 2014-02-28 2020-11-17 Brett Wolfe KIRKCONNELL Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde
DE102015017080B3 (en) 2014-02-28 2024-01-04 Gen-Probe Incorporated Method for isolating nucleic acid from cytological samples in liquid preservatives containing formaldehyde
WO2016014493A1 (en) 2014-07-22 2016-01-28 Bio-Rad Laboratories, Inc. Buffers for use with polymerases
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
DE102015220401B4 (en) 2014-10-20 2022-12-29 Gen-Probe Incorporated Erythrocyte Lysis Solution
EP3736346B1 (en) 2015-01-09 2023-12-20 Gen-Probe Incorporated Methods and compositions for diagnosing bacterial vaginosis
CA2977821A1 (en) 2015-03-16 2016-09-22 Gen-Probe Incorporated Methods and compositions for detecting bacterial nucleic acid and diagnosing bacterial vaginosis
US9957393B2 (en) 2015-03-30 2018-05-01 Enzo Biochem, Inc. Monoazo dyes with cyclic amine as fluorescence quenchers
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
WO2017098321A1 (en) 2015-12-11 2017-06-15 Spartan Bioscience Inc. Tube sealing system and methods for nucleic acid amplification
EP3400309A2 (en) 2016-01-04 2018-11-14 Gen-Probe Incorporated Methods and compositions for detecting candida species
AU2017207341A1 (en) 2016-01-12 2018-08-02 Interleukin Genetics, Inc. Methods for predicting response to treatment
EP3449015A1 (en) 2016-04-27 2019-03-06 Mira DX, Inc. Immune-based treatment of kras-variant cancer patients
DE202017007129U1 (en) 2016-04-27 2019-08-29 Gen-Probe Incorporated Lysis reagent for blood cells
EP3985131A1 (en) 2016-06-10 2022-04-20 Gen-Probe Incorporated Compositions and methods for detecting zika virus nucleic acid
WO2018005357A1 (en) 2016-06-27 2018-01-04 Abbott Molecular Inc. Compositions and methods for detecting zika virus
AU2017291727B2 (en) 2016-07-05 2021-07-08 California Institute Of Technology Fractional initiator hybridization chain reaction
US10815519B2 (en) 2016-08-30 2020-10-27 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
EP3529381B1 (en) 2016-10-19 2022-07-06 Gen-Probe Incorporated Compositions and methods for detecting or quantifying hepatitis c virus
AU2017363168B2 (en) 2016-11-21 2023-07-06 Gen-Probe Incorporated Compositions and methods for detecting or quantifying hepatitis B virus
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3057154A1 (en) 2017-03-24 2018-09-27 Gen-Probe Incorporated Compositions and methods for detecting or quantifying parainfluenza virus
CA3176536C (en) 2017-03-24 2024-03-05 Gen-Probe Incorporated Compositions and methods for detection of viral pathogens in samples
CA3056135C (en) 2017-03-25 2024-02-20 Gen-Probe Incorporated Compositions, methods and kits to detect adenovirus nucleic acids
JP7113842B2 (en) 2017-03-29 2022-08-05 クラウン バイオサイエンス,インコーポレイテッド(タイツァン) Systems and methods for determining cetuximab susceptibility of gastric cancer
WO2018209068A1 (en) 2017-05-11 2018-11-15 Gen-Probe Incorporated Compositions and methods for isolating target nucleic acids
AU2018281196B2 (en) 2017-06-07 2022-04-28 Gen-Probe Incorporated Detecting Babesia species nucleic acid in a sample
EP4286055A3 (en) 2017-07-10 2024-02-28 Gen-Probe Incorporated Analytical systems and methods for nucleic acid amplification using sample assigning parameters
US11859257B2 (en) 2017-08-11 2024-01-02 Gen-Probe Incorporated Compositions and methods for detecting Staphylococcus aureus
CN111465707A (en) 2017-11-17 2020-07-28 简·探针公司 Compositions and methods for detecting C1orf43 nucleic acids
WO2019118550A1 (en) 2017-12-13 2019-06-20 Gen-Probe Incorporated Methods for biological sample processing
EP3724354A1 (en) 2017-12-15 2020-10-21 Gen-Probe Incorporated Compositions and methods for detecting toxigenic clostridium difficile
EP3746225A1 (en) 2018-01-29 2020-12-09 Gen-Probe Incorporated Analytical systems and methods
GB2590210B (en) 2018-06-13 2023-01-25 Gen Probe Inc Compositions and methods for detecting group B Streptococcus nucleic acid
CA3105684A1 (en) 2018-07-10 2020-01-16 Gen-Probe Incorporated Methods and systems for detecting and quantifying nucleic acids
GB201812192D0 (en) 2018-07-26 2018-09-12 Ttp Plc Variable temperature reactor, heater and control circuit for the same
AU2019314449A1 (en) 2018-08-01 2021-03-11 Gen-Probe Incorporated Compositions and methods for detecting nucleic acids of Epstein-Barr virus
US20210310059A1 (en) 2018-08-08 2021-10-07 Gen-Probe Incorporated Compositions, methods and kits for detecting mycoplasma genitalium
WO2020041414A1 (en) 2018-08-21 2020-02-27 Gen-Probe Incorporated Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
JP7389111B2 (en) 2018-08-24 2023-11-29 ジェン-プローブ・インコーポレーテッド Compositions and methods for detecting bacterial nucleic acids and diagnosing bacterial vaginosis
WO2020069085A2 (en) 2018-09-27 2020-04-02 Gen-Probe Incorporated Compositions and methods for detecting bordetella pertussis and bordetella parapertussis nucleic acid
US20220017980A1 (en) 2018-10-01 2022-01-20 Gen-Probe Incorporated Compositions and methods for amplifying or detecting varicella-zoster virus
WO2020086546A1 (en) 2018-10-22 2020-04-30 Gen-Probe Incorporated Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus
TW202030333A (en) 2018-12-20 2020-08-16 美商簡 探針公司 Compositions and methods for detecting plasmodium species nucleic acid
WO2020142347A2 (en) 2018-12-31 2020-07-09 Gen-Probe Incorporated Systems and methods for filling multi-well cartridges with solid reagents
CA3127620A1 (en) 2019-01-25 2020-07-30 Gen-Probe Incorporated Detection of drug-resistant mycoplasma genitalium
WO2020197987A1 (en) 2019-03-22 2020-10-01 Gen-Probe Incorporated Compositions and methods for detecting group a streptococcus
CA3137749C (en) 2019-05-03 2023-12-05 Gen-Probe Incorporated Receptacle transport system for an analytical system
US20220249660A1 (en) 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
JP2022540801A (en) 2019-07-03 2022-09-20 ジェン-プローブ・インコーポレーテッド Oligonucleotides for use in determining the presence of Trichomonas vaginalis in a sample
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021041056A1 (en) 2019-08-23 2021-03-04 Gen-Probe Incorporated Compositions, methods and kits for detecting treponema pallidum
WO2021046270A1 (en) 2019-09-05 2021-03-11 Gen-Probe Incorporated Detection of chlamydia trachomatis nucleic acid variants
EP4058187A1 (en) 2019-11-14 2022-09-21 Gen-Probe Incorporated Compositions and methods for capturing target nucleic acids
WO2021133916A1 (en) 2019-12-23 2021-07-01 Abbott Laboratories Compositions and methods for detecting picobirnavirus
WO2021138325A1 (en) 2019-12-30 2021-07-08 Abbott Laboratories Compositions and methods for detecting bunyavirus
CA3174532A1 (en) 2020-03-04 2021-09-10 Gen-Probe Incorporated Compositions and methods for detecting sars-cov-2 nucleic acid
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
EP4146821A1 (en) 2020-05-07 2023-03-15 Grifols Diagnostic Solutions Inc. Methods and compositions for detecting sars-cov-2 nucleic acid
US20230243001A1 (en) 2020-07-17 2023-08-03 Gen-Probe Incorporated Detection of Macrolide-Resistant Mycoplasma Genitalium
CA3177256A1 (en) 2020-10-21 2022-04-28 Gen-Probe Incorporated Fluid container management system
JP7209980B2 (en) 2020-12-11 2023-01-23 東洋紡株式会社 An antibody that specifically binds to the 5' to 3' exonuclease active domain of a DNA polymerase
EP4284925A1 (en) 2021-01-26 2023-12-06 California Institute of Technology Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
AU2022237386A1 (en) 2021-03-15 2023-10-05 Gen-Probe Incorporated Compositions and methods for biological sample processing
EP4337797A1 (en) 2021-05-14 2024-03-20 Gen-Probe Incorporated Compositions and methods for detecting human adenovirus nucleic acid
CA3220932A1 (en) 2021-07-01 2023-01-05 Gen-Probe Incorporated Enzyme formulations and reaction mixtures for nucleic acid amplification
WO2023010008A1 (en) 2021-07-27 2023-02-02 Gen-Probe Incorporated Compositions and methods for detecting gastrointestinal pathogens
WO2023102459A1 (en) 2021-12-03 2023-06-08 Medicinal Genomics Corporation Psilocybe assay
WO2024044352A1 (en) 2022-08-26 2024-02-29 The General Hospital Corporation Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
WO2024054924A1 (en) 2022-09-08 2024-03-14 Gen-Probe Incorporated Method of detecting nucleic acid analytes using dual-specificity primers
WO2024059493A1 (en) 2022-09-13 2024-03-21 Medicinal Genomics Corporation Psilocybe assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006270A1 (en) * 1986-04-16 1987-10-22 The Salk Institute For Biological Studies Replicative rna reporter systems
EP0266319A2 (en) 1986-10-30 1988-05-04 Alaska di Pirazzi Alfonsino Improved apparatus for the deep-freezing of foods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4710464A (en) * 1984-09-27 1987-12-01 Eli Lilly And Company Transcription terminators
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1986006412A1 (en) * 1985-05-02 1986-11-06 Genetics Institute, Inc. Process and nucleic acid construct for producing reagent complexes useful in determining target nucleotide sequences
US4725537A (en) * 1985-09-19 1988-02-16 Allied Corporation Assay, reagent and kit employing nucleic acid strand displacement and restriction endonuclease cleavage
EP0224126A3 (en) * 1985-11-25 1989-02-01 The University of Calgary Covalently linked complementary oligodeoxynucleotides as universal nucleic acid sequencing primer linkers
AU6834187A (en) * 1985-12-17 1987-07-15 Genetics Institute Inc. Displacement polynucleotide method and reagent complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006270A1 (en) * 1986-04-16 1987-10-22 The Salk Institute For Biological Studies Replicative rna reporter systems
EP0266319A2 (en) 1986-10-30 1988-05-04 Alaska di Pirazzi Alfonsino Improved apparatus for the deep-freezing of foods

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHU, B.C.F.; KRAMER, F.R.; ORGEL, L.E.: "Synthesis of an Amplifiable Reporter RNA for Bioassays", NUCLEIC ACIDS RES., vol. 14, 1986, pages 5591 - 5603
HARUNA, I.; SPIEGELMAN, S.: "Autocatalytic Synthesis of a Viral RNA", IN VITRO, SCIENCE, vol. 150, 1965, pages 884 - 886
J. Biochem., Vol. 93, No. 3, 1983, Tohru Nishihara et al: "Localization of the Q Replicase Recognition Site in MDV-1 RNA", page 669-674. *
LIZARDI, P.M. ET AL.: "Exponential Amplification of Recombinant-RNA Hybridization Probes", BIO/TECHNOLOGY, vol. 6, October 1988 (1988-10-01), pages 1197 - 1203
MANIATIS, T.; FRITSCH, E.F.; SAMBROOK, J.: "MOLECULAR CLONING:A LABORATORY MANUAL", 1982, COLD SPRING HARBOR LABORATORY
MARCH ET AL.: "POSITIVE STRAND RNA VIRUSES", 1987, ALAN R. LISS
NATURE, Vol. 339, 1989, F.R. Kramer and P.M. Lizardi: "Replicatable RNA reporters", page 401 - 402. *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361983A2 (en) * 1988-09-30 1990-04-04 Amoco Corporation RNA template end-linked probe constructs and methods for use
EP0361983A3 (en) * 1988-09-30 1991-04-03 Amoco Corporation Rna template end-linked probe constructs and methods for use
US5763171A (en) * 1988-09-30 1998-06-09 Amoco Corporation Nucleic acid structures with catalytic and autocatalytic replicating features and methods of use
EP0481704A1 (en) * 1990-10-16 1992-04-22 Ciba Corning Diagnostics Corp. Amplification of midivariant DNA templates
US5959095A (en) * 1990-10-16 1999-09-28 Chiron Diagnostics Corporation Amplification of midivariant DNA templates
EP0692541A1 (en) * 1990-10-16 1996-01-17 Ciba Corning Diagnostics Corp. Amplification of midivariant DNA templates
EP0552931A1 (en) * 1992-01-22 1993-07-28 Gen-Probe Incorporated Hybridization assay using branched nucleic acid probes
US5451503A (en) * 1992-01-22 1995-09-19 Gen-Probe Incorporated Method for use of branched nucleic acid probes
EP0601889A2 (en) * 1992-12-10 1994-06-15 Maine Medical Center Research Institute Nucleic acid probes
US5607834A (en) * 1992-12-10 1997-03-04 Maine Medical Center Research Institute Fluorescent imperfect hairpin nucleic acid probes
EP0601889A3 (en) * 1992-12-10 1994-08-03 Maine Medical Center Res
JPH09504950A (en) * 1993-11-12 1997-05-20 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク Hybridization probe for nucleic acid detection, common stem, method and kit
EP2423322A1 (en) * 1993-11-12 2012-02-29 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
US6821727B1 (en) 1993-11-15 2004-11-23 Applera Corporation Hybridization assay using self-quenching fluorescence probe
EP0736103A1 (en) * 1993-12-17 1996-10-09 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
EP0736103A4 (en) * 1993-12-17 1999-07-28 Roger S Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
US6177247B1 (en) 1994-02-01 2001-01-23 The Regents Of The University Of California Detection methods using probes labeled with energy transfer coupled dyes for DNA fragment analysis
US6544744B1 (en) 1994-02-01 2003-04-08 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US5723591A (en) * 1994-11-16 1998-03-03 Perkin-Elmer Corporation Self-quenching fluorescence probe
US6030787A (en) * 1994-11-16 2000-02-29 Pe Corporation Hybridization assay using self-quenching fluorescence probe
US6258569B1 (en) 1994-11-16 2001-07-10 The Perkin-Elmer Corporation Hybridization assay using self-quenching fluorescence probe
US5876930A (en) * 1994-11-16 1999-03-02 Perkin-Elmer Corporation Hybridization assay using self-quenching fluorescence probe
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7413708B2 (en) 1995-05-05 2008-08-19 Applied Biosystems Inc. Methods and reagents for combined PCR amplification
US6485903B1 (en) 1995-05-05 2002-11-26 Pe Corporation (Ny) Methods and reagents for combined PCR amplification and hybridization probing
US7847076B2 (en) 1995-05-05 2010-12-07 Life Technologies Corporation Methods and reagents for combined PCR amplification
US7241596B2 (en) 1995-05-05 2007-07-10 Applera Corporation Methods and reagents for combined PCR amplification and hybridization probing
US6025133A (en) * 1996-12-30 2000-02-15 Gen-Probe Incorporated Promoter-sequestered oligonucleoside and method of use
WO1998029568A1 (en) * 1996-12-30 1998-07-09 Gen-Probe Incorporated Target-triggered amplification
EP0851033A1 (en) * 1996-12-30 1998-07-01 Gen-Probe Incorporated Target-triggered amplification
US7537886B1 (en) 1999-06-22 2009-05-26 Life Technologies Corporation Primers and methods for the detection and discrimination of nucleic acids
US6830902B1 (en) 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US8043816B2 (en) 1999-07-02 2011-10-25 Life Technologies Corporation Compositions and methods for temperature-dependent nucleic acid synthesis
US8946404B2 (en) 2000-05-09 2015-02-03 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US8440399B2 (en) 2000-05-09 2013-05-14 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
EP2316974A1 (en) 2000-05-09 2011-05-04 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
EP2333113A1 (en) 2000-05-09 2011-06-15 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7582432B2 (en) 2000-05-09 2009-09-01 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7109312B2 (en) 2000-05-09 2006-09-19 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US9018369B2 (en) 2000-05-09 2015-04-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US10301349B2 (en) 2000-05-09 2019-05-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US9139610B2 (en) 2000-05-09 2015-09-22 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US8410255B2 (en) 2000-05-09 2013-04-02 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US8633307B2 (en) 2000-05-09 2014-01-21 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US10041117B2 (en) 2001-10-23 2018-08-07 Life Technologies Corporation Primers and methods for the detection and discrimination of nucleic acids
WO2005073403A1 (en) * 2004-01-30 2005-08-11 Dade Behring Marburg Gmbh Test system and method for the detection of analytes
US7635598B2 (en) 2004-07-08 2009-12-22 Biosearch Technologies, Inc. Inducible fluorescence assay
US9803240B2 (en) 2008-04-01 2017-10-31 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
EP2757091A1 (en) 2008-04-01 2014-07-23 Biosearch Technologies, Inc. Stabilized Nucleic Acid Dark Quencher-Fluorophore Probes
US8466266B2 (en) 2008-04-01 2013-06-18 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
US8674094B2 (en) 2008-04-01 2014-03-18 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
WO2013113748A1 (en) 2012-02-02 2013-08-08 Primer Design Ltd Method for detecting and genotyping target nucleic acid

Also Published As

Publication number Publication date
AU4346689A (en) 1990-04-18
US5312728A (en) 1994-05-17
DK56091D0 (en) 1991-03-27
US5118801A (en) 1992-06-02
JPH07508398A (en) 1995-09-21
DK56091A (en) 1991-05-30
EP0436644B1 (en) 1996-04-17
AU647376B2 (en) 1994-03-24
JP2806455B2 (en) 1998-09-30
EP0436644A1 (en) 1991-07-17
DE68926302T2 (en) 1996-11-28
DE68926302D1 (en) 1996-05-23
FI911536A0 (en) 1991-03-28
ATE136941T1 (en) 1996-05-15
ES2023290A6 (en) 1992-01-01

Similar Documents

Publication Publication Date Title
US5312728A (en) Assays and kits incorporating nucleic acid probes containing improved molecular switch
EP0707076B1 (en) Method for determining analyte employing probe with replicable RNA template
US5112734A (en) Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna
AU599628B2 (en) Amplified hybridization assay
US5652107A (en) Diagnostic assays and kits for RNA using RNA binary probes and a ribozyme ligase
US6420539B1 (en) Replicatable hybridizable recombinant RNA probes and methods of using same
CA2070632A1 (en) Use of dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays
NZ235979A (en) Nucleic acid amplification employing a transcribable hairpin probe
EP0469755A1 (en) Method producing a polynucleotide for use in single primer amplification
AU2152099A (en) Specific and sensitive nucleic acid detection method
US5869260A (en) Nucleic acid-antibody constructs and their use in antigen detection
Kalisch Patent Number: 5,312,728 May 17, 1994 Date of Patent
WO1991018117A1 (en) Replicatable hybridizable recombinant rna probes and hybridization assay
AU1523799A (en) Methods and compositions for detection of specific nucleotide sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989911480

Country of ref document: EP

Ref document number: 911536

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1989911480

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989911480

Country of ref document: EP